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Abstract
In this thesis, a systematic study of the structural characterization
of the capsular polysaccharides of Streptococcus pneumoniae is con-
ducted using Molecular Modelling methods. S.pneumoniae causes
invasive pneumococcal disease (IPD), a leading cause of death in chil-
dren under five.
The serotypes in group 6 are amongst the most common of IPD caus-
ing serotypes. We performed structural characterization of serogroup
6 to understand the structural relationships between serotypes 6A,
6B, 6C and 6D in an attempt to understand the cross protection seen
within the group. The 6B saccharide has been included in the early
conjugate vaccine (PCV-7), and has shown to elicit protection against
the 6B as well as offer some cross-protection against 6A. 6A has since
been included in the latter conjugate vaccines in the hopes of eliciting
stronger protection against 6A and 6C.
Molecular Dynamics simulations were used to investigate the confor-
mations of oligosaccharides with the aim of elucidating a conforma-
tional rationale for why small changes in the carbohydrate primary
structure result in variable efficacy. We began by examining the Po-
tential of Mean Force (PMF) plots of the disaccharide subunits which
make up the Serogroup 6 oligosaccharides. The PMFs showed the
free energy profiles along the torsional angles space of the disaccha-
rides. This conformational information was then used to build the four
oligosaccharides on which simulations were conducted. These simu-
lations showed that serotype pairs 6A/6C and 6B/6D have similar
structures.
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Chapter 1
Introduction
Invasive pneumococcal disease (IPD) is a leading cause of death in children under
five, killing around a million children globally each year.2–6 IPD is the clinical con-
dition where Streptococcus pneumoniae infects normally sterile sites such as blood,
cerebrospinal fluid or pleural fluid. In addition to pneumonia, S.pneumoniae also
causes other diseases, such as: bacteremia, meningitis, sepsis, otitis media and
other mucosal and invasive diseases.1,4, 7, 8
S. pneumoniae is a gram-positive bacterium surrounded by a protective polysac-
charide capsule. Polysaccharides are carbohydrates comprised of long chains of
linked sugar monomers, which can join together in a variety of possible combina-
tions. There are also a number of linkages possible between two monosaccharides
and structural variation is further increased by the fact that these linkages have
great flexibility, which allows a carbohydrate to adopt a number of conformations.
It is suspected that the flexibility of the polysaccharide capsule accounts for the
powerful virulence of the bacteria, by delaying the host’s immune response.9–12
On the basis of the structure of the capsular polysaccharides, S.pneumoniae
is classified into over 90 different serotypes, a handful of which cause most of the
IPDs in the world.2,4, 13 In addition to differentiation, the capsular polysaccharide
acts as a virulence factor, as it inhibits the phagocytosis of the bacteria by the
host’s immune system.
Over the years, vaccine development against S.pneumoniae has advanced and
the latest conjugate vaccines have been shown to be effective in preventing dis-
ease in high risk population groups. Conjugate vaccines comprise of bacterial
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capsular polysaccharide antigens covalently linked to a carrier protein to enhance
the immunogenicity of the vaccine. While conjugate vaccines are effective, they
do not protect against all the serotypes causing IPDs. Nearly all the fatalities
caused by IPDs, occur in developing countries in Asia and Africa.7
IPD in South Africa
Consideration of the IPD burden is especially important in the South African
context. S.pneumoniae is commonly present in the South African population,
with bacteria present in six in every ten healthy adults, with immune systems
able to fight off the infection. However, the risk of IPD is greater in those who
are immunocompromised.14–16 South Africa has high HIV rates, which has in
turn increased the IPD burden in the country. This is specifically true within the
cohort of HIV infected children under five, which has contributed to the steadily
increasing under-five mortality rate in South Africa.17
The incidence of documented IPD in South African children has doubled in
the years following the onset of the HIV epidemic.17 75% of severe IPD in South
African children occurs within 6% of the population of HIV positive children
under five.16 A trial of a 9-valent conjugate vaccine in South Africa showed a
83% reduction in HIV-negative children and a 65% reduction in HIV-positive
children of vaccine serotype specific IPDs.16,17
South Africa has prioritized pneumococcal prevention, despite the high cost of
vaccines, as prevention of this disease is more cost effective than treatment. South
Africa was among the first of the industrializing countries and the first country
in Africa to introduce the pneumococcal vaccine into the public immunization
programme.14,17–19
Understanding Vaccines
One approach to improving conjugate vaccines is to increase the valency and thus
provide better coverage.20,21 This requires knowledge of which polysaccharides
might elicit an antibody response. Unfortunately, the relationship between car-
bohydrate sequence, antigenicity and immunogenicity is still not well understood.
An understanding of the three-dimensional structure of a polysaccharide will help
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explain their properties and functions and thus expand the range of serotypes cov-
ered by a conjugate vaccine.22 However, the extreme flexibility of carbohydrates
makes it difficult to determine their conformation experimentally. Traditional
experimental structural analysis methods, such as X-ray crystallography and nu-
clear magnetic resonance (NMR), can be used to determine saccharide structure
however, they are not without their shortcomings. Oligo- and polysaccharides
often do not have a single conformation, but occupy an ensemble of conforma-
tions in solution. It is this dynamic property of carbohydrates which makes them
difficult to characterize experimentally. X-ray crystallography provides a static
crystal structure and NMR data can provide structural information of carbohy-
drates in solution. However, this data is often an average of all the populated
conformation states and often requires Molecular Modelling studies for confirma-
tion.23–25 Molecular dynamics (MD) simulations of molecules are conducted with
well-defined empirical force fields which aim to realistically describe the system.
The results of these simulations shed light on the conformation adopted by these
molecules, which can then be used to explain the behaviour and functions of the
molecules.
1.1 Problem Statement - Serogroup 6
The Pneumococcal Vaccine Project (PATH) supports the development of afford-
able pneumococcal vaccines and vaccine manufacturers in the developing world
have to carefully choose the serotypes included in their vaccine to ensure a cov-
erage of at least 60% of the invasive disease isolates in the target region26 and
yet have sufficiently low valency to be affordable. The 7-valent pneumococcal
vaccine (PCV-7) has been one of the biggest success stories of conjugate vac-
cines and is available in South Africa. PCV-7 has dramatically reduced the
incidence of IPD, however its efficacy varies globally. It is most successful in the
United States and least in the developing world, where the majority of childhood
deaths occur.7,27 There has also been an increase in IPD cases due to non-vaccine
serotypes (serotype replacement) which has motivated the licensure of higher va-
lent vaccines PCV-10 and PCV-13 in order to increase vaccine coverage.
Serogroup 6 serotypes are amongst the most common cause of IPD in children
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and is the focus of this work.6 Serogroup 6 was originally comprised of type 6A
and 6B. Serotypes 6C and 6D were originally mistyped 6A and 6B respectively
and have recently been added to the group.28,29 Two points of difference account
for these four serotypes: a galactose or a glucose residue, and a (1→3) or a (1→4)
rhamnose-ribitol5P linkage:
6A: [→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]
6B: [→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]
6C: [→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]
6D: [→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]
Serotype 6B is more stable than 6A and is included in the early conjugate
vaccines (PCV-7 and PCV-10).7,30 Serotype 6B has been shown to not only
protect against IPD caused by 6B, but also offers some cross-protection against
6A.13,31–33 Serotype 6C was originally mistyped as 6A and is now found to cause
IPDs worldwide. The 6B antigen does not appear to offer any cross-protection
against 6C, which is currently the most prevalent serotype within group 6 to
cause IPD.33–36 Serotype 6D, was initially synthesized in the lab in 2009, and not
considered to be present naturally.37 However IPD caused by naturally occurring
6D has since been reported.6,28,32,38,39 The later conjugate vaccines (PCV-13 and
PCV-15) also include serotype 6A, and is suspected to induce protection against
6C and 6D but, this is yet to be clinically established.13,29
Currently there is no conformational rationale for the observed cross-protection
(the limited cross protection 6B offers 6A) and the predicted cross-protection (6A
and 6B cross-protecting against 6C and 6D) for serogroup 6.
1.2 Aim
The aim of this project is to develop a computational methodology to struc-
turally characterize the serogroup 6 serotypes, so as to investigate a structural
explanation for the cross-protectivity seen within the serogroup 6.
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1.3 Research Questions
The aim is to answer the following questions:
1. What effect does the αLRhap-DRibol-5P (1→3)/(1→4) linkage
change have on the structure of the serotypes? Serotype 6B, included
in conjugate vaccines PCV-7 and PCV-10, has shown to offer some cross-
protection against 6A.13,31,32,40 The only difference between 6A and 6B is
a (1→3)/(1→4) linkage. Can the structures explain this cross-protection?
2. What effect does a galactose/glucose residue change have on the
structure of the serotypes? With the introduction of PCV-7 into im-
munization schedules, there has been a global reduction in IPD incidences
brought on by 6A and 6B, however serotype replacement has taken place
and there has been an increase in 6C and 6D incidences. Serotypes 6C and
6D were previously identified as 6A and 6B and differ in a galactose/glucose
residue. Serotype 6A has thus been included in later conjugate vaccines
PCV-13 and PCV-15 in the hopes that the combination of 6A and 6B in
the vaccine will protect against the entire serogroup. Preliminary studies
have suggested that 6A offers 6C some cross-protection.13,29,41,42 Can the
structures shed light on this possible cross-protection?
3. Can a systematic approach to computational modelling of serogroup
6 provide insight into cross-protection observed between serotypes
6A/B/C/D? S.pneumoniae serogroup 6 are phosphodiester containing
saccharides with a linear ribitol sugar. This moiety increases the com-
plexity of the serogroup. Does the methodology used in this dissertation
shed light on the structures of this serogroup?
1.4 Approach
A systematic approach is used to study the oligosaccharide structures of serogroup
6 using Molecular Mechanics and Dynamics simulations.
The first step is to investigate the glycosidic linkage conformation by analyzing
the disaccharide components of serogroup 6. Ramachandran-like contour maps
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will be produced for these linkages (based on their φ and ψ torsion angles) which
detail the entire linkage conformational space and the disaccharide preferences. A
metadynamics routine, using φ and ψ dihedral angles as collective variables, will
be used to produce these potential of mean force landscapes giving insight into
the low energy conformations of the disaccharides. The optimum disaccharide
conformations are thus established and are used to build likely conformations of
the oligosaccharides on which Molecular Dynamics simulations are conducted.
After analyzing each of the disaccharide components, 3 repeating unit long
oligosaccharides will be built with their likely conformations. Molecular Dy-
namics simulations in vacuum of these oligosaccharides will be run to observe
convergence. The dihedral angles of the middle repeating unit will be plotted on
their previously calculated contour maps showing how interresidue interactions
affect the preferred conformations of the glycosidic linkages.
The converged conformations of the middle repeating unit of the serotype MD
simulations will be used to build 5-repeating unit long oligosaccharides which will
be minimized. These structures will allow for preliminary structural comparisons
of serotypes allowing for some indication of the effects of residue and linkage
differences on the conformations and hence possible sources of cross-protection.
However due to time constraints, no solution or ion effects can be established at
this point.
1.5 Thesis Overview
This thesis is organized as follows:
Chapter 2 is an introduction to carbohydrates and conjugate vaccines. It
begins with an outline of the various structural aspects of carbohydrates which
allow them to perform a variety of functions. This is followed by the history of
conjugate vaccines specifically against S.pneumoniae serogroup 6, the focus of
this work.
Chapter 3 then follows, outlining the computational theory and methods used
in Molecular Modelling, with attention given to the methods used in this work.
Chapter 4 details the methodology and specifications used in modelling both
the disaccharide subunits of serogroup 6 and the serogroup 6 oligosaccharides.
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Chapter 5 analyzes the disaccharide subunits of serogroup 6. We start by
looking at the effects the highly flexible and charged ribitol-phosphate disaccha-
rides. This is followed by an analysis of the remaining disaccharide structures,
comparing points of difference within the serogroup.
Chapter 6 studies the serogroup 6 oligosaccharide structures from Molecular
Dynamics simulations.
Lastly, Chapter 7 concludes this dissertation and provides possible areas of
further study.
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Chapter 2
Carbohydrate Structure and
Conjugate Vaccines
Carbohydrates, also known as saccharides, are an important class of bio-molecules,
making up most of the organic matter on Earth. The functions of saccharides
extend beyond primary energy stores and fuels to: metabolic intermediates, struc-
tural framework for DNA and RNA, and structural support molecules, for both
plant cell walls and animal exoskeletons. Carbohydrates are also found on the
surfaces of cells and play a key role in cell-cell recognition, and thus immunologi-
cal responses. The wide spectrum of functions that carbohydrates perform is due
to the large variety of structures and functionalities that they can adopt. The di-
versity of carbohydrates can be seen from the smallest class, the monosaccharides,
to the large complex polysaccharide molecules.24,43–48
2.1 Carbohydrate Structure
2.1.1 Monosaccharides
The simplest carbohydrates, known as monosaccharides, have the empirical for-
mula Cn(H2O)n, where n is greater than 2. In a monosaccharide, one carbon
atom bears a carbonyl group (C=O), while the other carbon atoms bear hydroxyl
groups (O-H). The position of the carbonyl group classifies a monosaccharide as
an aldose or ketose. If the sugar contains an aldehyde group (RC(=O)H), it is
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known as an aldose, while, if it contains a keto group (RC(=O)R’), it is a ketose.
This difference can be seen in Figure 2.1 below which shows two hexoses, the
aldohexose glucose and the ketohexose fructose.
Figure 2.1: Aldose glucose (a) and ketose fructose (b)
An aldose with n carbon atoms contains n-2 chiral centres and as a result
has 2n-2 stereoisomers. While, a ketose, with n carbon atoms, has n-3 chiral
centres and therefore possess 2n-3 stereoisomers. These stereoisomers are further
classified based on the position of the hydroxyl group at the Cn−1: L, when left,
and D when right. Most naturally occurring sugars are found as D stereoisomers.
Figure 2.2 shows the D and L stereoisomers of glucose.
Figure 2.2: D-glucose (a) and L-glucose (b)
Hydroxyls react with an aldol/ketone group to form hemiacetals/hemiketals
respectively. These reactions can occur through a neutral mechanism or an acid
catalyzed mechanism as seen in Figure 2.3.
9
Figure 2.3: Neutral and acid catalyzed mechanisms of hemiacetal and hemiketal formation
Monosaccharides often do not exist as open chains, but they often from ring
hemiacetals/hemiketals known as lactols when the aldol/ketone group react with
a hydroxyl group via the neutral mechanism shown in Figure 2.3. Most often
these ring structures are six-membered rings (pyranoses) or five-membered rings
(furanoses).
The formation of the ring structures gives rise to another possibility for variety
in saccharides. The closing of a saccharide produces two possibilities, an α and
a β anomer, as seen in Figure 2.4. Typically, hexose sugars in solution exist in a
dynamic equilibrium between the α and β anomers.
Figure 2.4: Intramolecular cyclization of glucose
Once cyclised these ring structures are not flat but rather take on a variety of
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configurations known as puckers, due to the tetrahedral geometry of the carbon
atoms. For pyranose rings, chair conformations are generally preferred, while the
configurations such as the boat and half-chair cause steric crowding of atoms,
leading to higher energies. The chair conformations are classified as either 4C1,
where C4 lies above and C1 lies below the plane of the ring, and 1C4, with C1
and C4 lying above and below the plane respectively. Pyranose saccharide rings
are said to be relatively rigid.22,43,46,49
Figure 2.5: 4C1 chair (a), 1C4 chair (b) and boat (c) conformations of pyranose rings
2.1.2 Gycosidic Linkages and Disaccharides
Two monosaccharides may be joined together by a glycosidic linkage to form a
disaccharide. A condensation reaction occurs, joining the anomeric carbon of
one monosaccharide to any of the hydroxyl groups on the second monosaccha-
ride. If the glycosidic linkage occurs between the two anomeric carbons of the
monosaccharides, there is no free lactol group and the disaccharide is known as
non-reducing, as it can no longer form further linkages with other saccharides. If,
on the other hand, the glycosidic linkage is from the anomeric carbon to any of
the non-anomeric hydroxyls, there will be a free lactol group and the disaccharide
is known as a reducing disaccharide. Reducing disaccharides are free to increase
in length by forming glycosidic linkages to further residues. Examples of reducing
and non-reducing disaccharides can be seen in Figure 2.6.
The conformation of disaccharides are primarily determined by their glycosidic
linkage. The glycosidic bond can be characterized by torsion angles φ and ψ and
in the case of a (1→6) linkage, an additional torsional angle ω. The definitions
of φ, ψ and ω are shown below (2.1). The φ and ψ torsion angle definitions are
different to the standard IUPAC definitions, but are analogues to IUPAC’s φH
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Figure 2.6: Reducing (a) and non-reducing (b) disaccharides
and ψH , and can therefore be translated when necessary.
φ = H1 − C1 −O1 − Cx
ψ = C1 −O1 − Cx −Hx
ω = O1 − C6 − C5 −O5
(2.1)
The conformational preference of the glycosidic torsional angles determines
how the monomers are oriented with respect to each other. Since monomers
rings are often comparatively rigid, the glycosidic linkages, determine the overall
conformation of the disaccharide.
Disaccharides are the smallest, and simplest, level of carbohydrate which pos-
sesses the qualities of a long polysaccharide chain. As a result studying disaccha-
ride conformation is the natural first step in studying polysaccharide conforma-
tions.46,47
2.1.3 Polysaccharides
Most carbohydrates exist as long chains of monosaccharides, which adopt com-
plex three-dimensional tertiary structures. These structures may be rigid, but
most often they are highly flexible and can adopt several conformations, allow-
ing for the variety of roles that they play. Determining the three-dimensional
structure of these flexible saccharides is a major challenge in glycobiology. It is
essential for a better understanding of their chemistry and in order to develop
carbohydrate based drugs.43,45,46,49,50 Typically, a saccharide chain of up to 20
12
monosaccharides is termed an oligosaccharide and one greater than 20 residues is
called a polysaccharide.
Nearly all polysaccharides are comprised of pyranoside residues which tend
to adopt the rigid chair conformations. As a result, the main contributor to
carbohydrate tertiary structures are the glycosidic bonds (φ, ψ and ω torsion
angles) that link the monomers. Therefore, a key step to determine carbohydrate
structure is characterizing the glycosidic linkages. These linkages are not easily
characterized as they are flexible, and the degree of flexibility varies from linkage
to linkage. Within a particular saccharide the linkages need not act independently
but often influence each other.22,43,46,49,51
2.2 Experimental Techniques to Study Carbo-
hydrate Structure
Carbohydrates structure is primarily studied using 1H and 13C NMR spectroscopy.
Homonuclear coupling constants, 3JH−H , are important in determining ring con-
formations and estimating the ω torsion angle. Linewidth temperature coeffi-
cients and low temperature hydroxyl 3JHO,C,H couplings are used to study hy-
drogen bonds.52 Nuclear Overhauser effects are also key in determining carbohy-
drate structure, 1H-1H NOE constants, shed light on intraresidue protons and, in
rare cases, on interresidue protons between consecutive monosaccharides. 1H-13C
NOEs as well as T1, T2 and T1p relaxation times detail distances between carbons
and hydrogens, and are used to determine glycosidic linkage conformations.53,54
Oligosaccharides show flexibility on short timescales, through angle and bond
vibrations, and longer times scales, through rotations of the dihedral angles. This
flexibility and internal motions complicate results obtained from NMR studies,
which do not sample at these timescales. Therefore, results obtained from NMR
studies represent an “average” structure and one has to be aware of the vari-
ous conformational permutations when interpreting spectra.45,49,50 As a result,
Molecular Mechanics (MM) and Molecular Dynamics (MD) simulations are often
used in conjunction with NMR techniques when studying carbohydrates, as they
help shed light on the dynamic properties of these molecules.24,25,55
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Other techniques such as Mass Spectrometry (MS) and X-ray crystallography
can also be used to shed light on structural information. Carbohydrates are of-
ten hard to crystallize for X-rays.24,49,50,56 One way of obtaining carbohydrate
crystals is by trapping them with proteins, either through covalent bonds or as
carbohydrate ligands for protein complexes. Results from X-ray crystallography
do not show dynamic characteristics of the molecules, but detail structural in-
formation such as torsion angles and hydrogen bonding with surrounding water
molecules. Mass Spectrometry is also used, as it is a highly sensitive requiring
requiring small sample amounts. MS, while useful, is unable to distinguish among
different stereoisomers, as they have the same mass.53,54
2.3 Carbohydrates and the Immune System
Bacterial capsular polysaccharides have several characteristics that aid in the
pathogen’s survival. The capsule, which is hydrophilic in nature, protects the
bacteria from dessication, which aids in host-to-host transmission. Once in a host,
the capsule also prevents opsonins, molecules that act as immune system targets,
from coating the bacteria, thus preventing phagocytosis and the activation of the
complement pathway. In some instances, the outer polysaccharide is the chemical
structure of molecules produced by human cells and as a result not recognized as
a foreign body by the immune system10,11,20,57
When recognized as a foreign body, the capsular polysaccharides of most
pathogenic bacteria act as T cell independent antigens. In this type immunity, the
T cell independent antigens directly interact with polysaccharide specific B-cells
which produce antibodies against the pathogen. For this mechanism, immunity
is often not developed in children under 2 years old. In addition to this, the
mechanism does not induce sustained memory.11
Glycoconjugates aim to change polysaccharides to T cell dependent antigens,
like proteins, and thus better the immune response. A glycoconjugate is formed
by covalently linking the carbohydrate to a protein carrier, most often a highly
immunogenic modified bacterial proteins such as: tetanus toxoid (TT), mutated
diphtheria toxin (CRM197) or outer membrane protein (OMP).
With glycoconjugates, the T cell dependent immune response is now possi-
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ble and involves two types of cells: B cells, which recognize the polysaccharide,
and helper T cells, which recognize the carrier. The T-cell dependent immune
response will now be induced through a series of steps. The response first starts
when the polysaccharide-protein hapten binds to the B cell receptors of polysac-
charide specific pre-B cells, and is enveloped into the endosome. In the cell, the
protein portion of the hapten is digested into peptide epitopes, regions of the anti-
gen which are recognized by the immune system. These peptides then bind to
protein molecules known as Major Histocompatibility Complex-Class II (MCHII)
molecules. The MCHII molecules carry the small regions of the antigen to the cell
surface and present them to the αβ receptor of the CD4+ T cells, activating them.
Once active, the T cells produce cytokines which are then released to stimulate
the maturation of the pre-B cells to B-cells, as well as induce immunoglobin class
switching from IgM to polysaccharide IgG. The B cells now release saccharide
specific IgG antibodies.11
2.4 Conjugate Vaccines
2.4.1 Use of Conjugate Vaccines
The Haemophilus influenzae type b, or Hib, conjugate vaccine was first licensed
in 1987 in the United States. Since its introduction into the vaccine schedules,
Hib vaccine has significantly reduced the incidence rate of disease in both de-
veloped and developing countries. The efficacy of the Hib conjugate vaccine
has been reported to be between 95-100%, which is a marked improvement over
the earlier polysaccharide vaccine, which was discontinued in 1988 in the United
States.58 Unlike its polysaccharide predecessor, Hib conjugate vaccines are im-
munogenic in high risk patients (infants, HIV-positive patients, etc.). Over the
years, the Hib polysaccharide, polyribosylribitol phosphate (PRP), has been con-
jugated to various protein carries: tetanus toxoid (TT), diphtheria toxoid (D),
mutant diphtheria toxin (CRM197) and outer membrane protein (OMP), to form
the conjugate polysaccharide vaccines.59
The success of the Hib conjugate vaccine promoted the development of con-
jugate vaccines against Neisseria meningitidis. The first N.meningitidis vaccine
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was a polysaccharide against serogroups A and C.60 Following this, a polysac-
charide vaccines against serogroups A,C and W135 as well as serogroups A, C,
W135, and Y were developed. These vaccines were not immunogenic in infants
which led to the development of conjugate vaccines. Meningococcal C conjugate
(MCC) vaccines were first developed and licensed in 1999. The serogroup C sac-
charides are conjugated to diphtheria or tetanus toxoid proteins.60,61 The use of
MCC has shown remarkable decrease incidence not just in those vaccinated, but
in non-vaccinated people as well due to herd immunity.61 A tetravalent conjugate
vaccine (A, C, Y, and W135) is also available in the United States and has shown
to be highly effective. N.meningitidis serogroup B causes 50% of meningococcal
disease in the world and is unfortunately is not currently protected against by
vaccines, as its outer polysaccharide (an α(2→8)linked N-acety-neuraminic acid
polymer) is present in human tissue and as a result is not recognized by the
immune system.60
2.4.2 Pneumococcal Vaccines
History of Pneumocccal Vaccines
The history of pneumococcal vaccines can be seen in Figure 2.7. The original
pneumococcal vaccines were whole cell vaccines, first introduced in 1918, ad-
ministered to the patient in two doses.10,62 These vaccines had very strong side
effects, and as a result, the 1920s saw the development of polysaccharide-based
vaccines.
In 1920, the capsular polysaccharides and nucleoproteins of the bacteria were
chemically isolated from bacterial cultures. When animals were immunized with
the capsular polysaccharides, it was found that serotype specific antibodies were
produced, and with the immunization of the nucleoproteins, general antibodies
to pneumococcus were produced. Unfortunately, the general antibodies were
poorly immunogenic while the type specific antibodies did elicit protection. This
lead to the development of vaccines, with the aim of combining the different
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Figure 2.7: History of Pneumoccoal Vaccines
polysaccharides to from a polyvalent vaccine which would protect against a range
of IPD causing serotypes.62
The first of these polyvalent vaccines, a four-valent vaccine, showed good
efficacy, protecting against serotypes 1, 2, 5, and 7.21,62 Despite its efficacy, the
then newly-developed hexavalent polysaccharide vaccine was withdrawn due to
the wide use of antibiotics such as penicillin.10 The eventual rise of antibiotic
resistant pneumococci renewed the interest in polysaccharide vaccines.10,62 From
the late 1960’s this interest led to the successful development of 14-valent and
then 23-valent polysaccharide vaccines.62 However, while polysaccharide vaccines
work well in healthy adults, they have failed to produce the same protection
for high-risk population groups, such as young children, the elderly, and people
infected with HIV.10,21
It was found that coupling pneumococcal polysaccharides to protein carriers
enhances the efficacy in the high risk population groups.20 These highly effective
conjugate vaccines do pose some challenges: the chemical conjugation of carbo-
hydrate to protein is technically difficult, the production of conjugate vaccines
is expensive, and conjugate vaccines only offer coverage for a limited number of
serotypes.20
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Current Status of Conjugate Vaccines against Streptococcus pneumo-
niae serogroup 6
Over the years, the development of vaccines against S.pneumoniae has made
progress and can be seen in Table 2.1. The first conjugate vaccine licensed against
S.pneumoniae is Prevnar/Prevenar (PCV-7), contained seven serotypes, includ-
ing serotype 6B. PCV-7 has been one of the biggest milestones in the prevention
of pneumococcal disease, and with its introduction into vaccine schedules new car-
riage and IPD due to PCV-7 serotypes has dramatically reduced, disease caused
by serotype 6B was nearly eliminated. In addition to this, it was also observed
that IPD due to 6A reduced, suggesting that 6B in PCV-7 offered some cross-
protection against 6A.63 While the introduction of PCV-7 has reduced IPD rates,
serotype replacement has been observed, and there was a noted rise in IPD from
non-vaccine serotypes (NVT). With respect to serogroup 6, there was a noted in-
crease in IPD caused by 6C, a serotype previously undistinguished from 6A.21,64
In Spain, it was shown that the prevalence of 6C increased with the introduction
of PCV-7. In children the prevalence of 6C, in the collected samples, was 0.1%
pre PCV-7, which increased to 1% post PCV-7.65,66 In adults, the study showed
that prevalence increased from 0.3% to 1.7% in the same period.65 A study in
Cleveland Ohio, noted that since the distribution of PCV-7, there has been an
increase in incidences caused by vaccine-related serotypes (207.4%), and non-
vaccine serotypes (18.4%).34 These increases were accounted for by mostly 19A,
6C, and 22F and serogroup 15.34 Serotype 6C is currently the most prominent
disease causing serotype of serogroup 6.
Vaccine Carrier Serotypes
PCV-7 CRM197 4, 6B, 9V, 14, 18C, 19F, 23F
PCV-10 DD/TT PCV-7 + 1, 5, 7F
PCV-13 CRM197 PCV-10 + 3, 6A, 19A
PCV-15 CRM197 PCV-13 + 22F, 33F
Table 2.1: Pneumococcal Conjugate Vaccines1
This prompted the development of higher valency conjugate vaccines, PCV-
10 and PCV-13, the latter also included serotype 6A. The inclusion of 6A in
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PCV-13 has been shown to induce a ten-fold greater response against 6A than
what was induced by PCV-7. In addition to this, the 6A conjugate also seems
to induce protection against 6C in recent studies. Cohen et. al. showed that
when vaccinated with PCV-13, the incidence of 6C was significantly lower than
in the population group that received the PCV-7 vaccine.4,31,67 Serotype 6D,
was initially synthesized in the lab in 2009, and not considered to be present
naturally. It has since been reported 6D has been identified to cause IPD in
South America, Fiji and Korea.6,28,32,38 It is yet to be determined if PCV-13
serotypes offer protection against 6D disease, as has been suggested, or if 6D is
an emerging serotype due to serotype replacement.
It is clear that there is a constantly changing epidemiology of predominant
serotypes, which calls for an increased coverage by the conjugate vaccines, as a
result PCV-15 is currently in development.42
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Chapter 3
Molecular Simulation
Molecular Modelling attempts to determine the “best” structure of a molecule,
and to use this information to explain the physical properties exhibited. Due
to their flexibility, carbohydrates are particularly difficult to simulate. Quantum
Mechanical principles are used to predict observable chemical properties from
first principles, by describing microscopic systems by “wave functions” that fully
describe all the physical properties of that system. However, it is often computa-
tionally impractical to simulate larger systems, such as oligosaccharide systems,
using Quantum Mechanics and thus various other methods, such as force field
methods are employed. Typically, Molecular Mechanics (MM) and Molecular
Dynamics (MD) force field methods are used to for carbohydrate simulations.
The basic principle of force field methods is to treat a system as a collection
of balls (atoms) and springs (bonds). The molecular system’s energy can then be
described mechanically, as a function of its resistance to bond stretching, angle
bending atom crowding etc.
3.1 Force Fields
The potential energy function of a molecule is defined as the sum of the energy
contributions from all bond stretching, angle bending, dihedral rotations, and all
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Figure 3.1: Ball and spring model
significant non-bonded atom interactions (Eq. 3.1).
E =
∑
bonds
Estretch +
∑
angles
Ebend +
∑
dihedrals
Etorsion +
∑
pairs
Enon−bond (3.1)
A force field consists of mathematical expressions and numerical parameters of
the terms above, the first three of which represent bonded potential terms and
the last non-bonded potential.
The bond stretch term in this equation models the energy of the bond (repre-
sented as a spring) when it is stretched or shortened past its equilibrium/natural
bond length. In the definition of Estretch (Eq. 3.2), kstretch is the bond force
constant, b is the bond length, and beq is the equilibrium bond length.
Estretch = kstretch(b− beq)2 (3.2)
The second term of the potential energy function, the angle bending term,
models the energies of angles corresponding to triatomic units, say atoms i-j-k
(Eq. 3.3). Just as with the bond stretching term, kbend is the bond force constant,
a is the angle currently formed by i,j,k, and aeq is the i,j,k angle equilibrium. The
second half of Ebend is known as the Urey-Bradley term, and models a non-covalent
spring between the outer atoms i and k. In this term, rik is the distance between
atoms i and k, rub is the equilibrium distance and kub, is the force constant. The
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Urey-Bradley term is only active when kub 6=0.
Ebend = kbend(a− aeq)2 + kub(rik − rub)2 (3.3)
The torsional term describes four sequentially bonded atoms, say i-j-k-l (Eq.
3.4). The dihedral angle, α is the angle between the plane created by atoms i-j-k
and the plane j-k-l. The integer constant n, where n ≥ 0, is a multiplicity term
which indicates periodicity. When n>0, k is the multiplicative constant and β,
is the phase shift angle which when n=0, is the equilibrium angle.
Etorsion
k(1 + cos(nα + β)), if n > 0k(α− β)2, if n = 0 (3.4)
The final term, the non-bonded term, calculates the van der Waals interac-
tions (the Lennard-Jones potential) and electrostatic interactions (the Coulomb
potential) of pairs of non-bonded atoms (Eq. 3.5). Calculating the non-bonded
interactions is the most computationally expensive step of a MD simulation. In
the Lennard-Jones potential, rij is the distance between a pair of atoms, Emin
is the well depth, and Rmin is the minimum interaction radius for the pair of
atoms. As the distance rij increases, the potential approaches 0 quickly, and so
a cut-off radius, after which all potentials are assigned as 0, is often specified to
reduce computational cost. The Coulomb potential measures the attractive and
repulsive forces between atoms based on atomic charges, here qiqj are the charges
on atoms i and j, C is the Coulomb’s constant, o is the dielectric constant, and
14 is a scaling constant.
Enon−bonded = ELJ + ECoulomb
where :
ELJ = (Emin)
[(
Rmin
rij
)12
− 2
(
Rmin
rij
)6]
and,
ECoulomb = 14
(
Cqiqj
orij
)
(3.5)
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3.2 Force Field Parameterization
The potential energy function is a mathematical function which has to be trans-
formed into an empirical force field. The empirical forcefield then relates chemical
structure and conformations to their energies. The process of fitting actual num-
bers to the equation parameters for each atom type (force constants, equilibrium
values angles etc.), pair (bond and non-bonded parameters), triplet (angle pa-
rameters), and quartets (dihedral parameters), is known as parameterization.
Parameterization of a force field is a difficult and tedious task as different
bonds and atom types have to be considered. A refined force field accounts for
multiple atom types and bonds. That is for example, there will be different
parameters to account for a sp2/sp2 C-C bond and a sp3/sp3 C-C bond.
Parameter values are obtained from a combination of experimental and ab ini-
tio calculations. The bond stretch and the angles bending parameters can usually
be obtained from experimental data, however obtaining experimental data for the
torsion and non-bonded parameters is considerably harder. As a result these pa-
rameters are often determined using theoretical quantum mechanics calculations.
3.3 Carbohydrate Force Fields
Over the years there have been significant improvements in carbohydrate force
fields, brought on, in large part, by the advances in computing and NMR spec-
troscopy. The increase in computing power has increased the number and com-
plexity of quantum mechanical simulations, which has allowed for parameteriza-
tion of atomic charge and torsional parameters from first principles, which were
not previously assignable based on existing experimental data. Improvements in
experimental techniques, particularly NMR, have also positively informed carbo-
hydrate parameters. In return, MD simulations are now routinely performed to
generate models which have been used to explain NMR results.68
Force fields are characterized into various classes, based on the properties of
their functional forms. The most widely used force fields belong to the Class I fol-
lowed by the Class II groups. Class I force fields are also known as quadratic force
fields, as their bond and angle terms are defined by quadratic terms. The pop-
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ular force fields: CHARMM, AMBER, and GROMOS all fall into this category.
These force fields model atoms as soft balls which are given static and partial
charges, held together with bonds modelled as harmonic springs. The functional
from of such force fields is generally of the form shown in Equations 3.1 - 3.5.
These biomolecular force fields were all initially developed for protein research,
but have since added parameter sets to model a wider range of biomolecules,
including carbohydrates. Class II force fields, such as MM3, MMFF, UFF and
CFF, have the same philosophy and ball-spring molecular model however their
functional forms are significantly more complex as they attempt to better handle
electronic effects. The sole force field used for the purpose of this work has been
the CHARMM force field.68
3.3.1 CHARMM Force Fields
CHARMM force fields were initially developed to model proteins, and parameters
for DNA, RNA, and lipids were subsequently added to CHARMM. Ha et al. were
the first to develop carbohydrate parameters for monosaccharaides, namely α-D-
glucopyranose.69
Following this, Reiling et al. developed carbohydrate parameters to extend
the CHARMM22 force field. The focus of this work was to develop accurate
torsional parameters using high-level ab initio calculations on molecules repre-
senting carbohydrate fragments, which showcased all the possible dihedrals in
non-substituted carbohydrates.70
Kuttel et al. derived a CHARMM Carbohydrate Solution Force Field (CSFF)
which took into account solvation and rotation of the primary and secondary
alcohols of a pyran ring.71
Hatcher et al. created new CHARMM carbohydrate parameters to include not
just hexopyranoses, but all possible glycosidic linkages between them, accounting
for chiralities, thus allowing for all un-substituted polysaccharides to be modelled.
The parameter set was further extended to include not just hexopyranoses, but
linear polyalcohols, inositol and linear sugars, using both experimental data and
QM calculations. These parameters were added to the CHARMM additive all-
atom force field which allows for the simulation of glycoproteins and glycolipids in
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addition to substituted polysaccharides.72–75 The CHARMM forcefield has been
further extended to include glyco-phosphates and glyco-sulphates.76
3.4 Energy Minimization
Energy minimization is often used in molecular conformational analysis. Here,
the conformational space is explored with the intention of finding atom positions
for which the force field function (Eq. 3.1) takes on its minimum value. At the
minimum, the first derivative of this function is zero and the second derivatives
are positive.
Minimization typically involves iteratively moving atomic positions to locate
the energy minimum. Several algorithms can be used for minimization, the most
popular being the steepest descent and conjugate gradient methods. The first
derivative minimization method, known as the conjugate gradient method, is
used to calculate the minima in this work, where points are moved based on the
initial direction of the point and its negative gradient. When minimized, atoms
are moved along gradients so as to reduce the forces on them, thus reducing their
potential energy.
Minimization does not guarantee that the global minimum in the conforma-
tional space is reached, but that the molecule is in its local minimum that it is in
a well on the potential energy surface. Molecules often have several local minima,
and as a result a minimization would find a local minimum that is closest to the
starting configuration of the search. In order to obtain a global minimum, one
will often have to carry out minimizations from various starting conformations.
3.5 Molecular Dynamics
Molecular Dynamics (MD) uses Newton’s equation of motion (Eq. 3.6a) in a
stepwise fashion, to calculate the movement of particles in a system caused by
forces brought on by the interaction of the system’s particles, where Fi, mi and
ai is the force, mass and acceleration of particle i. The equation can also be
represented as a gradient of the potential energy, E (Eq. 3.6b). The combination
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of Equations 3.6a and 3.6b produces Equation 3.6c, where E is the potential
energy of the entire system (Eq. 3.1) and r is the position of atom i.
Fi = miai (3.6a)
Fi = −∇iE (3.6b)
miai = − d
dri
E (3.6c)
The primary advantage of running a MD simulation is that one is able to see
details of the route taken, that is, a detailed time-dependent history of properties
and interaction is observable. In addition to this, a MD simulation will produce
an ensemble of conformations, unlike MM.
3.5.1 Numerical Integration
There are various possible methods that can be used to integrate the equations
of motion in a simulation such as: Gear predictor-corrector algorithms, Euler
algorithm, Verlet algorithm etc. The Verlet algorithm is the most popular and
for this work, the “velocity-Verlet” integration was used. This method starts by
calculating the velocity of the atoms between time steps (vn+ 1
2
) using the current
velocity (vn) and acceleration (M
−1Fn) of the atoms. This is then used to obtain
the positions and the forces of atoms for the next time step (rn+1, vn+1), which
in turn is used to calculate the velocity in the next time step (vn+1)
vn+ 1
2
= vn +M
−1Fn ·∆t/2,
rn+1 = rn + vn+ 1
2
∆t,
Fn+1 = F (rn+1),
vn+1 = vn+ 1
2
+M−1Fn+1 ·∆t/2
(3.7)
In order to reduce computational costs, NAMD uses a multiple time step
integration scheme. Here short-range forces consisting of bonded terms and van
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der Waals and electrostatic terms within a local distance are calculated at every
time step. Long-range forces, van der Waals and electrostatic interactions at
greater than the local distances, are calculated less frequently as they change
more slowly. The choice of time step size is very important, the smaller the time
step the more accurate the simulation, which comes at a computational cost.
Typically, a time step of 1 to 2fs is chosen for the short range calculations while
the long range forces may be calculated up to every 5fs.
3.6 Simulation Ensembles
A MD simulation can be conducted under various ensembles. Often a microcanon-
ical ensemble is used and here the number of atoms n, the volume of the unit cell
V and the total energy E or the total entropy S of the system is conserved. Under
the nVE ensemble as energy is conserved, entropy is maximised and conversely,
as entropy is conserved energy is minimized under the nVS ensemble.
An alternative to the microcanonical ensembles, are the canonical ensembles.
Here the system is immersed in an infinite heat bath, which maintains an almost
constant temperature, without any particle exchange. The two alternatives are
nVT, a constant number of atoms, volume, and temperature, and nPT, a constant
number of atoms, pressure and temperature, ensembles.
Temperature can be maintained by a variety of methods such as velocity
rescaling, weak coupling with the heat bath using a Berendsen thermostat, stochas-
tic collision such as an Anderson thermostat, or Langevin dynamics.
3.7 Simplifications
MD simulations are very tedious and computationally expensive, and there are
several techniques used to reduce the calculations in the simulation.
3.7.1 Periodic Boundary Conditions
Bulk systems are modelled using periodic boundary conditions. Using this method,
a central cell, often cubically shaped, is replicated and surrounded by its images.
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All the particles, in the cell and its images, move identically. When a particle
leaves the central cell from one side, an image of this particle re-enters from the
opposite end of the cell (Figure 3.2). In doing so, the surface effects are elimi-
nated, that is a particle doesn’t disappear from the cell as it exists. This allows
a large bulk system to be simulated, while keeping track of just a few particles
at a low computational cost.
Figure 3.2: 2D representation of periodic boundary conditions
3.7.2 Non-bonded Interactions
Calculating the non-bonded interactions for the potential energy function is the
most expensive part of a simulation (Eq. 3.5). This is a pairwise calculation,
calculating the interaction of all the atom pairs, and as a result computational
cost is N2, proportional to the square of the number of atoms. This expense is
reduced by using non-bonded cut-off distances.
van der Waals
The Lennard-Jones potential term is used to calculate the van der Waals inter-
actions between non-bonded atoms. When a cut-off distance is specified, van der
Waals interactions are not calculated between atoms which are further than the
cut-off distance. All atom pairs, beyond this distance, are assumed to have a
potential of zero. Smooth switching and a switching distance may also be set;
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after the switching distance the potential is smoothly lowered so as to arrive at
zero by the cut-off distance. This can be seen in the figure below (Figure 3.3).
Figure 3.3: Lennard-Jones potential when cut-off is applied
Electrostatic Interactions
Electrostatic interactions are calculated in a similar fashion as the van der Waals
interactions (Figure 3.4). When a cut-off is specified, atom pairs that are at a
greater distance than the specified cut-off distance are assumed to have an elec-
trostatic interaction energy of zero. When switching is activated (Figure 3.4 a),
the potential is shifted so as to reach zero by the cut-off. Full electrostatic inter-
actions (Figure 3.4 b), can also be calculated when multiple time step integration
is employed; electrostatic interactions below the cut-off distance are calculated
every time step and those beyond this distance are only calculated periodically.
Full electrostatic interactions may also be calculated using the Particle Mesh
Ewald method (PME). The PME method calculates the short-range electrostatic
interactions as a direct sum, and long range interactions are a sum in Fourier
space. The terms in the Fourier space converge quickly and as a result can be
truncated effectively, reducing computational cost.
3.7.3 Langevin Dynamics
The previous simplifications are used to reduce computational resources when
explicit solvent molecules are part to the simulated system system. However often
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Figure 3.4: Electrostatic interactions with switching (a) or with full electrostatics (b)
even with these simplifications, the simulations are too computationally expensive
and solvents are thus implicitly included. Implicit solvents can be simulated using
Langevin Dynamics, which simulate the effects of solvent molecules on the solute,
without adding them to the system.
Langevin Dynamics (Eq. 3.8) modifies the equation of motion of atom i with
the addition of two terms which simulate solvent interactions.
miai = Fi − γiv +Ri(t) (3.8)
γiv describes the frictional force of the implicit solvent on the solute particles.
This term opposes motion and is proportional to the particle’s velocity. Different
solvents can be simulated by altering the frictional coefficient γi.
The Ri(t) term describes the stochastic forces caused by thermal fluctuations
of the solvent on the solute molecule. When the two terms, frictional forces and
stochastic forces, are set to zero, the Langevin equation (Eq. 3.8) reduces to
Newton’s equation of motion (Eq. 3.6a).
3.7.4 Constraint Dynamics
Constraint algorithms are used to make certain high frequency bonds rigid, that
is holding them at a fixed bond length and angle. In doing so, it allows the
simulation to take larger time steps. This is particularly useful when large systems
are being modelled.
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The most common method used to do this is the SHAKE algorithm which
works in the Cartesian coordinates. During the dynamics simulation, atoms ini-
tially move first without any constraints, the magnitude of the constraints are
then calculated and the algorithm is readjusted. The SHAKE algorithm is used
most often to constrain water bonds or bonds involving hydrogen atoms.
3.8 Enhanced Sampling Methods
Molecular simulations have a huge influence on a variety of problems, but these
techniques are often limited by computational time. It is useful to calculate the
a Potential of Mean Force (PMF) which details the change in free energy along
reaction coordinates, such as a change in conformation. A PMF can be computed
when the simulation has sampled the potential energy surface throughly.
However, the progression of a simulation is hugely impacted by the starting
structure(s) of the system; that is, a simulation started near one minimum well
might find it very difficult to move into another well on the potential energy
surface unless highly favourable conditions are met. The probability of these
favourable conditions occurring, and thus a transition from one well to another,
might be low. As a result the progression of a simulation is heavily time depen-
dent, and enhanced sampling methods can be used to get over energy barriers.
There are various methods to accelerate the occurrence of such favourable con-
ditions such as: Adaptive Biasing Force, Umbrella Sampling and Free Energy
Perturbation, to name a few.77
3.8.1 Metadynamics
Metadynamics is used in this work and is closely related to Umbrella Sampling.
It computes free energies and aims to accelerate rare events in the simulations.
Metadynamics works by moving along a trajectory defined by a chosen set of
Collective Variables (CVs) which adds a bias to influence the dynamics of the
system. A normal MD simulation is biased in the direction of lower free energy
and Metadynamics aims to correct this bias by adding repulsive Gaussians po-
tentials centred on the current position of the system on the potential energy
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surface. As the system moves along the trajectory followed by the CVs, Gaussian
potentials are added to the free energy space. Adding these potentials discour-
ages the system to revisit previous configurations and enabling the system to
jump over saddle points into new minimum wells. The history dependent poten-
tial function of the energy surface (VG(s,t)) can then be calculated as a sum of
these Gaussians, producing a PMF surface.
Critical to Metadynamics is the choice of the CVs (s = sx, x = 1,...,n), which
define the trajectory. The CVs need to be chosen so as to describe the configu-
rational properties of the investigated molecules as completely as possible, thus
reducing the investigation to just the dimensions of the CVs.
The height (h), width (w), and frequency of deposition (t) define the Gaus-
sians (Eq. 3.9), and is critical to how accurately and quickly the PMF can be
constructed, larger Gaussians lead to a faster the exploration of the conforma-
tional space but produce a coarser PMF. The width (w) of the Gaussian determine
the resolution of the PMF, and the rate at which the Gaussians are added is the
Gaussian height (h) divided by the frequency of deposition (t).
h · exp(−|s− s(t)|
2
2w2
) (3.9)
The history dependent potential VG(s,t) is then constructed as a sum of Gaussians
centered at the explored point (s), value of the CV, up till time t (Eq. 3.10).
VG(s, t) = h
∑
ti
exp
(
−|s− s(ti)|
2
2w2
)
(3.10)
Over time, the sums of the Gaussians will reproduce the free energy F(s) (Eq.
3.11). That is, if dynamics is run for long enough the inverse of VG(s,t) will
produce PMF.
lim
t→∞
VG(s, t) ≈ −F (s) (3.11)
The use of an enhanced sampling method such as Metadynamics allows for
the production of a PMF surface which will shed light on the the conformational
preferences of the molecules being investigated.
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Chapter 4
Modelling Methods
This work follows a systematic approach to study the structures of the serogroup
6 saccharides. The methodology used for this investigation can be seen in Figure
4.1.
Figure 4.1: Overall methodology used for this study
The progression of a simulation depends on the starting structure(s) of the
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system; that is, a simulation started near one minimum well might find it very
difficult to move into another well on the potential energy surface unless highly
favourable and unlikely conditions are met. As a result, it is important to get a
good starting structure for the oligosaccharide.
This investigation begins by modelling disaccharide subunits that make up
the serotypes. This is done to investigate the properties of the disaccharides
themselves, and to use their optimum configurations to build a good starting
structure for the serotype oligosaccharides.
4.1 Disaccharides
Studying disaccharide substructures of an oligosaccharide so as to understand
the conformational preferences of the glycosidic linkages is often the first step to
studying oligosaccharide structure, and has been used in previous studies.78–82
Torsion angles of a glycosidic linkage are the major contributor to saccharide
flexibility and conformation. Producing Ramachandaran-like contour plots to
represent the linkage’s conformational preferences is becoming increasingly com-
mon.22,51,83 The energy landscape, or potential of mean force (PMF), plots of a
linkage are thus a function of the φ and ψ torsion angles of the disaccharide. These
PMF plots indicate regions of low energy and therefore predict the disaccharide
structure.
Two classes of disaccharide components were investigated. In the first class,
the disaccharides were a result of treating the ribitol-phosphate na¨ıvely as a
residue and thus the following disaccharides were studied:
αdGalp(1→3)αdGlcp and αlRhap(1→3)dRibol5P and
αdGlcp(1→3)αdGlcp αlRhap(1→4)dRibol5P
dRibol5P(O→2)αdGlcp and αdGlcp(1→3)αlRhap
dRibol5P(O→2)αdGlcp
Ribitol-phosphate, being a linear sugar residue, is highly flexible and as a re-
sult a second disaccharide class was considered where the dRibol5P was treated
a substituent to the αdGalp/αdGlcp(1→3)αdGlcp and αdGlcp(1→3)αlRhap
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linkages. In this class, the glycosidic linkage involving the dRibol5P was left to
relax while the linkage between the other two residues was intensionally explored.
As a result the following disaccharides were studied:
dRibol5P(O→2)αdGalp(1→3)αdGlcp and
dRibol5P(O→2)αdGlcp(1→3)αdGlcp
αdGlcp(1→3)αlRhap(1→3)dRibol5P and
αdGlcp(1→3)αlRhap(1→4)dRibol5P
The torsion angles for the dRibol5P(O→2)αdGalp/Glcp linkages are defined
as φ = PO3-P-O2-C2 and ψ = P-O2-C2-H2. For all the other disaccharides, the
torsion angles for a (1→n) linkage are defined as φ = H1-C1-O1-Cn and ψ =
C1-O1-Cn-Hn. These dihedral angles can be seen in Figure 4.2 on disaccharides
αdGalp(1→3)αdGalp and dRibol5P(O→2)αdGalp.
Figure 4.2: Dihedral angles on disaccharides αdGalp(1→3)αdGalp (a) and dRibol5P(O→2)αdGalp (b). φ is
seen in blue and ψ is seen in purple.
Torsion angles are classified as syn when they fall in between 0◦ and ±90◦,
or anti when they are in between ±90◦ and ±180◦. Disaccharides torsion angles
φ/ψ can thus be classified as syn/syn, syn/anti, anti/syn, or anti/anti depending
on their dihedral angles, which can be seen in Figure 4.3.
In this work, the atoms of the non-reducing residue are labeled using numbers,
atoms on the reducing residue are labeled with a primed number and when ribitol-
phosphate is treated as a substituent, its atoms are labeled with double primed
numbers.
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Figure 4.3: Disaccharides’ syn and anti classification
4.2 Oligosaccharides
Three repeating unit long (12mers) oligosaccharides were built using the global
minima calculated from the disaccharide energy landscapes. The serogroup 6
oligosaccharides are:
6A: [→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]
6B: [→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]
6C: [→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]
6D: [→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]
Two sets of oligosaccharides were built first using the global minima from the
class 1 disaccharides and secondly using the global minima from the class 2 dis-
accharides.
Molecular Dynamics simulations were conducted on these oligosaccharides.
Simulations were conducted in an nVT ensemble with implicit solvation. Implicit
solvation was accomplished by conducting the simulations in vacuum with a high
dielectric constant so as to reduce computational costs.
The conformation of the glycosidic linkages of the middle repeating unit
through the course of the simulation were analyzed as they will most accurately
relay polysaccharide information. These dihedral angles of the middle repeating
36
unit are plotted on their previously calculated contour maps showing how inter-
residue interactions affect the preferred conformations of the glycosidic linkages.
20mer (five repeating unit) oligosaccharides were then built using the confor-
mational preferences of the oligosaccharides seen from the MD simulations. The
most populated conformation of the glycosidic linkages of the middle repeating
unit from the final 100 ns of the MD simulations were used to build the 20mers,
with subsequent minimization, to show the two most prevalent structures for
each of the serotypes. This gives some insight into the possible structures of the
serogroup 6 saccharides.
4.3 Simulation Conditions
4.3.1 NAMD, VMD, and force fields
NAMD was used to conduct all the simulations in this work. Version 2.8 for Linux-
x86 64-multicore was used for the metadynamics simulations, and version 2.9 for
Linux-x86 64-MPI was used for oligosaccharide simulations.84 VMD version 1.8.7
for LINUXAMD64 was used for all the visualization.85
The CHARMM carbohydrate force field (C36) was used for all the simula-
tions.76 Serogroup 6 are phosphodiester containing saccharides and the phosphate
parameters in this force field were adapted for the Ribol5P(O→)αdGalp/Glcp
linkages.
4.3.2 Disaccharides - Metadynamics
A metadynamics protocol in NAMD was set up to investigate the disaccharide
conformational preferences about the conformational space (-180◦ to 180◦ for
φ and ψ torsion angles.) Collective variables are defined and used to alter the
dynamics of the system around a defined set of coordinates. Therefore, in this case
the collective variables were defined as φ and ψ. Each of the collective variables
were then rotated between -180◦ to 180◦ in 2.5◦ increments. The Gaussians were
defined with a weight and height of 3 and 0.1 respectively.
The class 1 disaccharides (standard disaccharides) simulations were run for
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400ns, while the disaccharides in class 2 (disaccharides with a ribitol-phosphate
substituent) were were run for 1200ns to allow the ribitol-phosphate to set-
tle into low energy conformations. The Gaussian parameters and simulation
times have to be in the chosen carefully in order to accurately recreate the
energy landscape.77 Well chosen parameters will ensure that the entire col-
lective variable space is explored through the course of the simulation. Fig-
ure 4.4 shows that this is the case for disaccharides αdGalp(1→3)αdGlcp and
dRibol5P(O→2)αdGalp(1→3)αdGlcp and that therefore appropriate parame-
ters were chosen.
Figure 4.4: Distribution of the φ and ψ angles of disaccharides αdGalp(1→3)αdGlcp (a) and
dRibol5P(O→2)αdGalp(1→3)αdGlcp (b)
Validation: β-maltose
In order to validate the metadynamics protocol, a simulation of maltose (αdGlcp
(1→4)βdGlcp) was conducted. The PMF of maltose, calculated with the meta-
dynamics method, compares to the previously calculated umbrella sampling vac-
uum PMF (Figure 4.5).86 Both PMF plots were produced using the same CSFF71
forcefield, therefore allowing for all similarities and differences to be attributed
to the sampling methods themselves.
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Figure 4.5: PMFs of maltose (αdGlcp(1→4)βdGlcp) calculated using method detailed in Section 4.3.2 (a) and
by Kuttel et. al. (2005)86 (b). Both PMFs show the energy contours at 2 kcal/mol increments from 0 kcal/mol
to 10 kcal/mol. The pink crosses show the distribution of φ/ψ vaules of maltose from Table 4.1
A visual inspection of the two PMFs shows that the two PMFs are very
similar. The low energy regions in both plots are conserved with the lowest
energy well located at the syn/syn position. Metadynamics does produce PMFs
that have more jagged contours than umbrella sampling, however the general
shape of the syn/syn, and syn/anti wells are conserved. The global minimum
from both these calculations are also in agreement, with the umbrella sampling
producing a global minimum of φ,ψ= -22.5◦, -25◦, while the global minimum of
maltose calculated in this work is at φ,ψ= -21.25◦,-26.25◦. Metadynamics does
show a small anti/syn well, not produced by the umbrella sampling, however this
well has a much higher energy than the syn/syn and syn/anti wells and is unlikely
to be occupied. Numerous other maltose studies have been conducted, both
experimental and theoretical (Table 4.1). The global minimum, φ,ψ= -21.25◦,-
26.25◦, of this work is in close agreement with most of these published literature
values, all of which do fall into the first contour of the low energy syn/syn wells
seen in 4.5. This, along with the close agreement of these two energy landscapes
in Figure 4.5 confirms that the umbrella sampling and metadynamics produce
similar outputs.
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Technique Used
NMR X-Ray MM/MD QM
φ,ψ φ,ψ φ,ψ φ,ψ
-31.5, -24.552 -23.2, -14.887 -32.8, -19.546 -47,-32.888
-48, -3047
-22.7, -21.789
-25.3, -13.952
-40, -3190
Table 4.1: Literature φ,ψ (◦) values of β-maltose
4.3.3 Oligosaccharide Simulations
Molecular dynamics simulations in an nVT ensemble were conducted in vacuum
on each of the eight oligosaccharides (four with unsubstituted dihedral values
and four with substituted dihedral values). A 300 K temperature was maintained
using a Langevin thermostat with a damping coefficient of 1/ps. No electrostatic
cutoffs were set thus all electrostatic interactions were calculated. A dielectric
constant of 78.5 was used to approximate water and all covalent bonds involving
hydrogen atoms were constrained to their equilibrium length using the SHAKE
algorithm. The simulations were minimized for 13 ps, followed by a production
run of 500 ns and the equations of motion were integrated using the Leap-Frog
Verlet integrator with a 1 fs integration timestep.
For the analysis of the simulation trajectories, the dihedral angles of the mid-
dle repeating unit of the three repeating unit long oligosaccharides were plotted
on the corresponding PMF surfaces to show the dihedral occupancy of the link-
ages throughout the course of the simulation. The most populated dihedral angles
of the glycosidic linkages from the final 100 ns of the simulations were used to
build 20mers of the serotypes, with subsequent minimization, to show the two
most prevalent structures for each of the serotypes.
4.3.4 Building Carbohydrate PDB files
All the investigated saccharides were built using CarbBuilder, inhouse software
which uses existing pdb structure files of sugar residues to build the saccha-
rides.91 The builder retrieves sugar pdb structures from text input (for exam-
ple “aDGlc(1→4)aDGlc” for maltose), creating the requested bonds between the
residues, and rotating the residues to either preset or user defined dihedral values,
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finally writing out a pdb file of the newly created structure. CarbBuilder allows a
user to build a variety of structures from disaccharides to regular polysaccharides
including branched structures.
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Chapter 5
The Glycosidic Linkages of
Serogroup 6
In this chapter, the energetically prefered conformations of each of the disaccha-
ride subunits of the S.pneumoniae serogroup 6 serotypes are identified. As stated
in Chapter 2, disaccharides are the simplest carbohydrates exhibiting properties
of longer polysaccharide chains46,47 and are often the first focus in a study of
carbohydrate conformation.25
The first step is to analyze the PMF plots of the glycosidic linkages of the dis-
accharide subunits that comprise serogroup 6, by performing detailed free energy
analysis of the φ and ψ dihedral angles of the glycosidic linkage. The disaccha-
rides are analyzed to so as to gain an understanding of their optimal structures,
which will be used to build likely starting structures for the oligosaccharide MD
simulations.
The structures of the serogroup 6 serotypes are:
6A: [→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]
6B: [→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]
6C: [→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]
6D: [→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]
These oligosaccharides were divided into disaccharide subunits for individual anal-
ysis as shown in Figure 5.1. Modelling the serogroup 6 serotypes is particularly
challenging, as these saccharides contain the flexible ribitol-phosphate moiety.
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Ribitol is unique among the residues of the serogroup in that it is a linear alditol
and possesses a high degree of internal conformational freedom. This makes anal-
ysis of the linkages containing ribitol challenging, which is further complicated by
the presence of the phosphodiester linkage. Ribitol thus has a potentially large
effect on the overall secondary structure of the serotypes.
The analysis of disaccharide subunits begins with ribitol-phosphate being
treated as a standard residue. This treatment results in the division of the
serogroup into seven disaccharides, henceforth labeled 1, 2, 3, 4 and primes,
which indicate serotype variations relative to 6A (class 1 in Figure 5.1).
1: dRibol5P(O→2)αdGalp (6A and 6B)
1′: dRibol5P(O→2)αdGlcp (6C and 6D)
2: αLRhap(1→3)dRibol5P (6A and 6C)
2′: αLRhap(1→4)dRibol5P (6B and 6D)
3: αdGalp(1→3)αdGlcp (6A and 6B)
3′: αdGlcp(1→3)αdGlcp (6C and 6D)
4: αdGlcp(1→3)αlRhap (6A, 6B, 6C and 6D)
The flexibility of the ribitol-phosphate prompted a second division of the
serotypes, this time into trisaccharides, effectively treating the ribitol-phosphate
as a substituent on a residue. This results in the division of the serotypes into
four trisaccharides, namely r3, 4r and their primes (class 2 in Figure 5.1).
r3: dRibol5P(O→2)αdGalp(1→3)αdGlcp (6A and 6B)
r3′: dRibol5P(O→2)αdGlcp(1→3)αdGlcp (6C and 6D)
4r: αdGlcp(1→3)αlRhap(1→3)dRibol5P (6A and 6C)
4r′: αdGlcp(1→3)αlRhap(1→4)dRibol5P (6B and 6D)
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Figure 5.1: Illustration of the division of S.pneumoniae serotype 6A into subunits. Fragments are classified
into two classes. Class 1 contains disaccharides and class 2 contains trisaccharides where the ribitol is effectively
treated as a substituent. Arrows indicate the glycosidic linkage of interest. Other serotypes have equivalent
divisions.
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5.1 Disaccharides containing ribitol-phosphate
The disaccharides containing with ribitol-phosphate are examined so as to inter-
rogate the flexibility the linear alditol containing disaccharides: dRibol5P(O→2)
αdGalp (1), dRibol5P(O→2)αdGlcp (1′), αlRhap(1→3)dRibol5P (2) and
αlRhap(1→4)dRibol5P (2′).
5.1.1 DRibol5P(O→2)αDGalp and
DRibol5P(O→2)αDGlcp (Group 1)
Ribitol-phosphate is (PO→2) linked in serotypes 6A and 6B to a αdGalp (1) and
in serotypes 6C and 6D to a αdGlcp (1′)(Figure 5.2).
Figure 5.2: Structure of 1: dRibol5P(O→2)αdGalp and 1′: dRibol5P(O→2)αdGlcp
The PMF surface of 1 and 1′ (Figure 5.3 (a and b) and Table 5.1) confirms
that these are very flexible linkages with a large number of small energy wells.
The global energy minimum is located in the syn/anti (well A) position, but the
anti/anti conformation (well B) is almost equally favourable. Three wells (A,
B, and C) are within 2 kcal/mol of the global minimum and four wells within
4 kcal/mol (C, D, E and F). This can be accounted for by the bond between
the residues (PO→2) which results in a flexible ribitol tail, that may bend in
numerous ways to form a variety of stabilizing hydrogen bonds.
The highly similar PMF surfaces calculated for the dihedral linkages 1 and
1′ shows that the substitution of a glucose for a galactose does not alter the
preferred conformation of the linkage significantly. This is to be expected from
the structural similarity of the molecules: galactose is a C4 epimer of glucose
(Figure 5.2), a point of difference far removed from the glycosidic linkage. Figure
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5.3 (c) shows a difference plot of molecules 1 and 1′, and shows the minimal
difference between these linkages. The difference plot highlights that the biggest
difference between the two PMFs is in the ψ-syn region where the galactose
disaccharide is higher in energy. As 99.7% of the area of the two PMF plots is
within a difference of 2 kcal/mol, the rest of this discussion will be limited to
disaccharide 1.
Conformational Region
syn-φ/syn-ψ syn-φ/anti-ψ anti-φ/syn-ψ anti-φ/anti-ψ
φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF
dRibol5P(O→2) -63.75 -78.75,(2.42),E 63.75 161.25,(0.00),A 171.25 23.75,(1.98),D 166.25 163.75,(0.28),B
αdGalp 51.25 -71.25,(3.57),F -46.25 153.75,(1.20),C 156.25 -53.75,(2.96),G
1 (6A,6B)
dRibol5P(O→2) -61.25 -76.25,(1.69),E 56.25 158.75,(0.00),A 173.75 21.25,(1.05),D 168.75 153.75,(0.86),B
αdGlcp 46.25 -66.25,(2.70),F -48.75 148.75,(1.34),C 158.25 -66.25,(1.28),G
1′ (6C,6D)
Table 5.1: Minima in energy wells of dRibol5P(O→2)αdGalp and dRibol5P(O→2)αdGlcp. φ/ψ (◦), ∆G
(kcal/mol), corresponding region on PMF in Figure 5.3
Wells A, B and C and wells E, F, and G are separated by approximately 120◦
along the φ dihedral angle. Figure 5.3 (d) shows snapshots of the molecules from
the labeled regions on the PMF, with the stabilizing hydrogen bonds indicated.
Snapshots of the A, B and C wells (the 2kcal/mol wells), reveal that the 120◦
rotation about φ allows for two interresidue hydrogen bonds to form between
the hydroxyl groups adjacent to the linkage (OH1′ and OH3′) and the phosphate
oxygens (O5 and OPs). The snapshots from the 4kcal/mol wells (D, E, F, and G)
shows one hydrogen bond between the OH1′ or OH3′ hydroxyls and the phosphate
oxygens (O5 and OPs), accounting for the lower energy seen in A, B and C. Wells
E, F and G give the corresponding “flipped” conformations with respect to A, B
and C of the molecule with the glactose ring rotated by 180◦ about the ψ dihedral.
The snapshots also highlight the flexibility of the ribitol residue: in snapshots
from regions: A, C, E and F ribitol-phosphate forms bended ring-like structures,
yet in regions B, D and F the ribitol-phosphate has adopted a more extended
structure from the galactose residue.
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Figure 5.3: The potential of mean force (PMFs) plots of (a) dRibol5P(O→2)αdGalp, (b)
dRibol5P(O→2)αdGlcp (the global minimum is indicated by the black diamonds (φ,ψ = 63.75◦, 161.25◦ on (a)
and φ,ψ = 56.25◦, 158.75◦ on (b)) and contours are at 2kcal/mol increments). (c) Difference plot of (a) and
(b), blue regions indicate higher energies seen in molecule 1 and red indicates higher energies seen in 1′. (d)
snapshots of the conformations of the molecule corresponding to the labeled regions of the PMF (a).
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5.1.2 αLRhap(1→3)DRibol5P and
αLRhap(1→4)DRibol5P (Group 2)
Serogroup 6 has two different rhamnose-ribitol-phosphate linkages (Figure 5.4):
αlRhap(1→3)dRibol5P in 6A and 6C (fragment (2) in Figure 5.1) and αlRhap
(1→4)dRibol5P in 6B and 6D (2′).
Figure 5.4: Structure of 2:αlRhap(1→3)dRibol5P and 2′: αlRhap(1→4)dRibol5P
The φ, ψ free energy profiles of the glycosidic linkages in 2 and 2′ (Figure 5.5)
reveal a considerable difference between the (1→3) and (1→4) linkages. While
the global minimum for both the disaccharides is in the syn/syn position (Table
5.2), there is a considerable shift between the two minima, with about a 100◦ flip
on both φ and ψ: -46.25◦, -36.25◦ for 2 and 56.25◦, 63.75◦ for 2′.
Conformational Region
syn-φ/syn-ψ syn-φ/anti-ψ anti-φ/syn-ψ anti-φ/anti-ψ
φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF
αlRhap(1→3)dRibol5P -46.25 -36.25,(0.00),A -21.25 -171.25,(0.88),C -168.75 -6.25,(1.39),B -91.25 176.25,(7.48)
2 (6A,6C)
αlRhap(1→4)dRibol5P 56.25 63.75,(0.00),A -13.75 -178.25,(5.01),C -171.25 -21.25,(1.68),B -91.25 146.25,(9.96)
2′ (6B,6D) -91.25 -46.25,(2.55),D
Table 5.2: Minima in energy wells of αlRhap(1→3)dRibol5P and αlRhap(1→4)dRibol5P. φ/ψ (◦), ∆G
(kcal/mol), corresponding region on PMF in Figure 5.5
Disaccharide 2 has three broad minima: A, B and C, while 2′ shows a different
landscape: a shift in well A, an additional well D found in between well A and B
and the loss of well C (the region has a 2 kcal/mol contour at 2 which is around
6 kcal/mol for 2′).
This shows that the (1→3) linkage has a larger number of conformational
options around ψ than the (1→4) linkage when φ is restricted to a syn conforma-
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Figure 5.5: Potential of mean force (PMF) plots for (a) αlRhap(1→3)dRibol5P (global minimum at φ,ψ
= -46.25◦, -36.25◦) and (b) αlRhap(1→4)dRibol5P (global minimum at φ,ψ = 56.25◦, 63.75◦). The global
minima are indicated by the black diamonds, contours are at 2kcal/mol increments and the energy along the
drawn paths on the PMFs are shown along side the PMF plots.
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tion. However, the additional well D for the (1→4) linkage gives 2′ conformational
options about the ψ angle not possible for the (1→3) linkage.
Figure 5.6 shows representative conformations corresponding to the regions
labeled on the PMF plots. The highly flexible ribitol-phosphate bends to form
hydrogen bonds both with other hydroxyl groups on the ribitol and to other
residues. Figure 5.6, shows that most often (regions A, C and D), the ribitol
bends forming a ring-like structure through an intraresidue hydrogen bond across
the length of the ribitol: between PO′-O1′ and/or PO′-O2′. In addition to the
ring-forming intraresidue hydrogen bonds, the B conformation snapshot for both
molecules shows a stabilizing interresidue hydrogen bond between O2-O4′ in 2
and between O2-OP′ in molecule 2′. There is a difference in the global minimum
(A) of the two molecules, which is nearly a reflection about the line ψ = -φ.
This causes the ribitol orientation, with respect to the rhamnose residue, to be
flipped. That is, for molecule 2, the phosphate end of the ribitol is far away
from the glycosidic linkage, rather than adjacent to the glycosidic linkage as in
molecule 2′.
Possible paths of transitions between the low energy wells on the PMF plots
were explored. The energy along these paths was extracted using the in house
Heightmap Analyzer tool.92 The energy along these paths, shown alongside the
PMF plots in Figure 5.5 (a and b), gives a good indication of the energy barriers
between the wells. For molecule 2 (the (1→3) linkage) transitions between A and
B must occur over barriers W (7 kcal/mol) and X (9 kcal/mol). Barriers Y and
Z, between the A and C regions, are approximately the same height (9.5 and 9
kcal/mol respectively), however Y is a wider and less steep. Based on these data,
it is more likely that transitions between A and B would occur over the W barrier
and between wells A and C would occur over barrier Y. For 2′ the two barriers
X and Y, between the A and B/C conformations, are equally likely to be crossed
as they are of the similar heights (8 kcal/mol).
The flexibility of the ribitol-phosphate thus demonstrated, prompted the in-
vestigation of the effects of ribitol-phosphate on ribitol adjacent disaccharide link-
ages.
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Figure 5.6: Examples of conformations of αlRhap(1→3)dRibol5P and αlRhap(1→4)dRibol5P corresponding
to the labeled regions of the PMFs (Fig 5.5 (a and b))
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5.2 Pyranose disaccharides
There are three linkages in serogroup 6 involving only pyranose residues: αdGalp
(1→3)αdGlcp (3), αdGlcp(1→3)αdGlcp (3′), and αdGlcp(1→3)αlRhap (4).
The PMF profiles for these linkages were calculated twice, firstly as the un-
substituted disaccharides (3, 3′, and 4) and secondly with a ribitol-phosphate
substituent attached to the appropriate residue of the disaccharides (r3, r3′, 4r
and 4r′).
Ribitol-phosphate is added to these disaccharides in order to investigate its
effects on the adjacent disaccharide linkage, which will give a better indication of
an appropriate disaccharide orientation in serogoup 6. The Ribitol-5P is attached
to the appropriate residue of the respective disaccharides and the conformational
space of the torsional angles between the galactose-glucose, glucose-glucose and
glucose-rhamnose is intentionally explored while the ribitol is left unconstrained.
5.2.1 αDGalp(1→3)αDGlcp and αDGlcp(1→3)αDGlcp
(Group 3)
The serotypes 6A/6B and 6C/6D differ in that 6A and 6B contain components 3
(αdGalp(1→3)αdGlcp) or r3 (dRibol5P(O→2)αdGalp(1→3)αdGlcp), while 6C
and 6D contain components 3′ and r3′ (where the galactose residue is replaced by
a glucose residue). The structures of the unsubstituted and substituted linkages
can be seen in Figure 5.7. The PMFs around the αdGalp(1→3)αdGlcp and the
αdGlcp (1→3)αdGlcp linkages are calculated in order to investigate the effects
of the αdGalp/αdGlcp change on the (1→3) linkage.
Unsubstituted disaccharides
The αdGlcp(1→3)DGlcp disaccharide is commonly referred to as nigerose. A
variety of experimental and theoretical studies have been conducted to determine
the conformation of β-nigerose (αdGlcp(1→3)βDGlcp), an anomer of 3′ at C1 of
the reducing residue. It is expected that β-nigerose would exhibit similar results
to its α anomer and thus the results from this study can be compared.
Table 5.3 summarizes the previous results which are also plotted on Figure 5.8
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Figure 5.7: Structure of the αdGalp(1→3)αdGlcp and αdGlcp(1→3)αdGlcp disaccharides
(b). The global minimum of α-nigerose, -25.25◦,-23.75◦, and the literature results
in Table 5.3, including the most far removed quantum mechanical result, fall
within the low energy syn/syn well (A) of 3′, with nearly all the results falling
within the first 2kcal/mol contour [Figure 5.8 (b)]. Taking into consideration
the anomeric difference of the disaccharides, experimental shortcomings, as well
variation in modelling techniques and forcefields, this agreement helps to validate
the nigerose results calculated in this work.
Technique Used
NMR X-Ray MM/MD QM
φ,ψ φ,ψ φ,ψ φ,ψ
-38.8, -22.652 -20.1, -15.887 -24, 047 -46.77, -3388
-24.3, 0.646
-34.8, 47.489
-22.7, 193
-35.6, -9.652
Table 5.3: Literature φ,ψ values of β-nigerose. These values are plotted on the α-nigerose plot (Fig 5.8 (b))
The PMF plots of disaccharides 3 and 3′ [Figure 5.8 (a) and (b)], have a
principal energy well (A) between -60◦ and 0◦ for φ and -60◦ and 60◦ for ψ. For
both the unsubstituted disaccharides, the global minimum falls in this syn/syn
(A) conformational region (-21.25◦,-23.75◦). In addition to the principal well,
the disaccharides have a secondary syn/anti (B) well. The low energy wells are
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approximately at 150◦ intervals about ψ, with φ constricted between -60◦ and 0◦
(Table 5.4).
Conformational Region
syn-φ/syn-ψ syn-φ/anti-ψ anti-φ/syn-ψ anti-φ/anti-ψ
φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF
αdGalp(1→3)αdGlcp -21.25 -23.75 (0.00),A -26.25 -173.75 (1.61),B -91.25 -33.75 (6.49) -91.25 166.25 (10.98)
3 (6A,6B)
αdGlcp(1→3)αdGlcp -21.25 -23.75 (0.00),A -28.75 -171.25 (2.11),B -91.25 -23.75 (7.44) -91.25 151.25 (10.40)
3′ (6C,6D)
Table 5.4: Minima in conformational regions of αdGalp(1→3)αdGlcp and αdGlcp(1→3)αdGlcp. φ/ψ (◦), ∆G
(kcal/mol), corresponding region on PMF in Figure 5.8
The difference plot of the 3 and 3′ PMFs [Figure 5.8 (c)] highlights the sim-
ilarities of the two disaccharides, the energy profiles of these molecules is within
2.3 kcal/mol. Both 3 and 3′ show nearly identical energy profiles [Figure 5.8 (a
and b)] and minima, with 99.9% of the energy difference between the two plots
equal to or lower than 2 kcal/mol, as seen the the difference plot.
In the low energy conformations, two potential hydrogen bonds may form
between the oxygens adjacent to the glycosidic linkage between: O2 or O5 and
O2′ or O4′. Figure 5.9 shows snapshots of the two molecules in the A and B
labeled minima showing stabilizing hydrogen bonds. The snapshots of the global
energy minimum (A) of 3 shows stabilizing hydrogen bonds on either side of the
glycosidic linkage, while the global minima of 3′ shows one of these hydrogen
bonds (O2-O4′). The secondary well snapshots (B), (a 150◦ rotation about ψ)
also show these interresidue hydrogen bonds between O5-O4′ for 3 and O2-O2′
for 3′. Both molecules have two identical energy barriers, X and Y, between their
wells A and B. However, barrier X is approximately 6.5 kcal/mol high, which is
2 kcal/mol lower than the barrier at Y. Thus, transitions between A and B wells
are likely to go over barrier X.
The similarity of the profiles of these two molecules is to be expected, as the
only point of difference is the C4 hydroxyl: axial in galactose and equatorial in
glucose (Figure 5.7). This steric difference is far removed from the glycosidic
bond and, as a result, has minimal effects on the energy profiles.
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Figure 5.8: The potential of mean force (PMFs) plots of (a) αdGalp(1→3)αdGlcp, (b) αdGlcp(1→3)αdGlcp,
(d) dRibol5P(O→2)αdGalp(1→3)αdGlcp and (e) dRibol5P(O→2)αdGlcp(1→3)αdGlcp. The contours are at
2kcal/mol increments and global minimum is indicated by the black diamonds ( φ,ψ = -21.25◦,-23.75◦ for (a)
and (b), φ,ψ = -21.25◦,-23.75◦ for (d) and φ,ψ = -21.25◦,-23.75◦ for (e)) The pink crosses on the 3′ plot (b)
indicate the locations of nigerose calculated in Table 5.3. Difference plots (c) of 3 and 3′ and (f) of r3 and r3′,
blue regions indicate higher energies seen in molecule 3/r3 and red indicates higher energies seen in 3′/r3′.
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Figure 5.9: Examples of conformations of αdGalp(1→3)αdGlcp and αdGlcp(1→3)αdGlcp corresponding to
the labeled regions of the PMFs (Fig 5.8 (a and b))
Substituted disaccharides
The PMF plots of r3 and r3′ are shown in Figure 5.8 (d) and (e). These plots
show two energy wells, the primary anti/syn well (B) and a secondary syn/syn
well (A).
In comparison to 3 and 3′, the central A well has narrowed and split into
two adjoining smaller wells. The biggest effect of the ribitol-phosphate on these
disaccharides is to shift the global minima from the syn/syn position [Figure 5.8
(a) and (b)], to a syn/anti position: r3 at -28.75◦,-158.75◦ and r3′ at -28.75◦,-
163.75◦. With the addition of the ribitol, the syn/syn conformation is now about
3-4kcal/mol higher than the new global minimum for both molecules. This sec-
ondary minima of these molecules sits at -38.75◦,-21.25◦ for r3 and -53.75◦,-28.75◦
for r3′ (Table 5.5).
Looking at the difference plot of the two PMFs [Figure 5.8 (e)], 84.5% of the
plot falls within 2 kcal/mol. While this difference (between r3 and r3′) is greater
than the difference between unsubstituted disaccharides (99.9%), it is located in
the φ-anti region of the molecules, which is unlikely to be occupied as it falls
above the 16 kcal/mol contour.
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The wells A and B are approximately 150◦ apart along ψ, while φ is constricted
mainly between -60◦ and 0◦. This is similar to the unsubstituted disaccharides
(3 and 3′). The addition of the ribitol-phosphate does alter the degree of confor-
mational freedom of the molecules, and this can be seen in the energy barriers
between the wells. With the addition of the ribitol-phosphate, the Y barrier is
heightened, from 8kcal/mol for the unsubstituted linkages to 10 kcal/mol for the
substituted linkages, and barrier X is been made wider, suggesting that the ad-
dition of the ribitol reduces the flexibility of the molecules. The extension of the
B well of r3 results in a more gradual climb to barrier X than r3′ which would
suggest that for the substituted disaccharides, r3 has greater conformational free-
dom than r3′. Given the height difference of 4 kcal/mol between barriers X and
Y, one would expect majority of the transitions between the A and B wells of
these molecules to occur over barrier X, particularly for r3, due to the extended
B well at barrier X.
Conformational Region
syn-φ/syn-ψ syn-φ/anti-ψ anti-φ/syn-ψ anti-φ/anti-ψ
φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF
dRibol5P(O→2) -38.75 -21.25 (1.20),B -28.75 -158.75 (0.00),A -91.25 -53.75 (5.36) -91.25 -91.25 (10.80)
αdGalp(1→3)αdGlcp
r3 (6A,6B)
dRibol5P(O→2) -53.75 -28.75 (2.06),B -28.75 -163.75 (0.00),A 176.25 -8.75 (5.44) -91.25 -91.25 (11.73)
αdGlcp(1→3)αdGlcp
r3′ (6C,6D)
Table 5.5: Minima in energy wells of dRibol5P(O→2)αdGalp(1→3)αdGlcp and
dRibol5P(O→2)αdGlcp(1→3)αdGlcp. φ/ψ (◦), ∆G (kcal/mol), corresponding region on PMF in Fig-
ure 5.8
Figure 5.10 shows snapshots of conformations of the molecules in their low
energy wells. For the unsubstituted disaccharides, hydrogen bonds formed, in
various combinations, between O2/O5 and O2′/O4′. However, the addition of
the ribitol-phosphate to C2 has altered this, as hydrogen bonds are now formed
with the phosphate oxygen atoms instead of O2. The snapshots of both molecules
in their global minimum (B) shows hydrogen bonds between O5-O4′ and PO-O2′,
while snapshots of the molecules in their secondary minima (A) shows a PO-O4′
hydrogen bond.
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Figure 5.10: Examples of conformations of dRibol5P(O→2)αdGalp(1→3)αdGlcp and
dRibol5P(O→2)αdGlcp(1→3)αdGlcp corresponding to the low energy regions of the PMFs (Fig 5.8 (d
and e))
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5.2.2 αDGlcp(1→3)αLRhap (Group 4)
The αdGlcp(1→3)αlRhap (4 Figure 5.11) disaccharide is common to the four
serotypes of serogoup 6. Though this linkage does not vary across the serotypes,
it is important to know its conformational preferences to understand the over-
all structure of the serotypes. The αlRhap residue, the only L-sugar in the
serogroup, is also linked to the ribitol-phosphate in two ways: through a (1→3)
linkage (6A and 6C, 4r) and a (1→4) (6B and 6D, 4r′). These adjacent ribitol
linkages might have an effect on the conformation that linkage 4 adopts in the
serotypes, and as such it has been studied here.
Figure 5.11: Structure of the αdGlcp(1→3)αlRhap disaccharides
Unsubstituted disaccharide
Figure 5.12 (a) shows that αdGlcp(1→3)αlRhap (4) has two energy wells: a
large principal syn/syn energy well and a smaller anti/syn energy well. The
global minimum for the molecule sites at φ,ψ= -43.75◦, -28.75◦ (Table 5.6).
Conformational Region
syn-φ/syn-ψ syn-φ/anti-ψ anti-φ/syn-ψ anti-φ/anti-ψ
φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF
αdGlcp(1→3)αlRhap -43.75 -28.75 (0.00), B -18.75 173.75 (2.32), A -91.25 -51.25 (5.17) -91.25 -91.25 (8.30)
4 (6A,6B,6C,6D) -33.75 43.75 (1.49), C
Table 5.6: Minima in conformational regions of αdGlcp(1→3)αlRhap. φ/ψ (◦), ∆G (kcal/mol), corresponding
region on PMF in Figure 5.12
The PMF plot of 4 shows a similar structure to the calculated landscapes of
the other (1→3) linked disaccharides discussed in Section 5.2.1. However, the
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Figure 5.12: The potential of mean force (PMFs) plots of (a) αdGlcp(1→3)αlRhap, (b)
αdGlcp(1→3)αlRhap(1→3)dRibol5P and (c) αdGlcp(1→3)αlRhap(1→4)dRibol5P. The contours are at
2kcal/mol increments and global minimum is indicated by the black diamonds ( φ,ψ = -43.75◦,-28.75◦ for
(a), φ,ψ = 43.75◦,-3.75◦ for (b) and φ,ψ = -43.75◦,-178.75◦ for (c))
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large syn/syn well is more extended along ψ when compared to the landscapes of
3 and 3′, while φ is still limited to -60◦ to 0◦. The two wells are approximately a
140◦ rotation about ψ apart. The two energy barriers X (7 kcal/mol) and Y (9
kcal/mol) between the wells are comparable to the barrier heights calculated for
molecules 3 and 3′.
Figure 5.13 (b) shows 4 in its low energy conformations with B and C falling
in the syn/syn well and A from the syn/anti well. Hydrogen bonds between hy-
droxyls adjacent to the glycosidic linkages form in these conformations stabilizing
the molecules. Conformations B and C, from the syn/syn well show stabilizing
hydrogen bonds between O5-O4′ and O6-O4′. The secondary minimum snapshot,
A, also shows these bonds between: O5-O2′ and O2-O4′. This is consistent to
with the hydrogen bonds observed in the other pyranosyl disaccharides 3 and 3′.
Figure 5.13: Examples of conformations of αdGlcp(1→3)αlRhap corresponding to the labeled barriers of the
PMF (Fig 5.12 (a))
Substituted disaccharide
The PMF plots [Figure 5.12 (b and c)] of the substituted molecules [αdGlcp(1→3)
αlRhap (1→3)dRibol5P (4r) and αdGlcp(1→3)αlRhap(1→4)dRibol5P (4r′)]
shows a dramatic change in the energy landscape with the substitution of the
ribitol-phosphate. While the anti/syn well has remained unchanged, what used
to be a single syn/syn well in the unsubstituted disaccharide, has been split to
four (B,C,D and E in 4r) and three (B,C, and D in 4r′) syn/syn wells. Thus
the addition of the ribitol-phosphate has increased the conformational options
along φ for the linkage. The PMFs demonstrate that has 4r more freedom than
4r′, with one extra syn/syn energy well (E) along the conformational space. In
61
addition to the extra energy well, 4r also has lower energy barriers between wells,
which suggest that the (1→3) substituted disaccharide is more flexible than the
corresponding (1→4) disaccharide. The global minimum of the two molecules
also differ with 4r at 43.75◦,-3.75◦, and 4r′ at -43.75◦,-178.75◦ (Table 5.7).
Conformational Region
syn-φ/syn-ψ syn-φ/anti-ψ anti-φ/syn-ψ anti-φ/anti-ψ
φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF φψ,(∆G),PMF
αdGlcp(1→3)αlRhap 43.75 -3.75 (0.00), C -38.75 173.75 (1.30), A 91.25 36.25 (3.66) -91.25 -101.25 (8.74)
(1→3)dRibol5P -23.75 -13.75 (1.53),B
4r (6A,6C) -73.75 -41.25 (1.76),E
68.75 56.28 (2.71),D
αdGlcp(1→3)αlRhap 41.25 8.75 (1.19), C -43.75 -178.75 (0.00), A 91.25 38.75 (2.92) -91.25 -96.25 (8.57)
(1→4)dRibol5P -8.75 -33.75 (1.83),B
4r′ (6B,6D) 88.75 38.75 (1.53),D
Table 5.7: Minima in energy wells of αdGlcp(1→3)αlRhap(1→3)dRibol5P and
αdGlcp(1→3)αlRhap(1→4)dRibol5P. φ/ψ (◦), ∆G (kcal/mol), corresponding region on PMF in Fig-
ure 5.12
The ribitol-phosphate forms stabilizing hydrogen bonds in the disaccharides
in all the conformational regions (Figure 5.14). The conformations of these
molecules are held in place not just by hydrogen bonds between the glucose and
rhamnose residues, but with the ribitol-phosphate as well. The trend of hydroxyls
adjacent to the glycosidic linkage forming stabilizing hydrogen bonds (between
O2/O5 and O2′/O4′) is somewhat conserved, however the snapshots in Figure
5.14, shows the flexible ribitol-phosphate orientates its phosphate end causing
hydrogen bonds to form with the phosphate oxygens instead.
It is worth noting, that the preference for the formation of hydrogen bonds
between the ribitol-phosphate and hydroxyls adjacent to the glycosidic linkage,
seen in the snapshots in Figure 5.14, is likely to be greatly reduced as the phos-
phate motif responsible for these hydrogen bonds is linked via a (O→2) linkage
to a galactose or glucose residue. The linkage to a glucose or galactose would
increase the constraints on this motif, reducing its ability to form the hydrogen
bonds. In addition to this, the doubly linked ribitol (through a rhamnose (1→3)
or (1→4) linkage and a (PO→2) linkage to a galactose or glucose) is likely to
severely reduce the internal flexibility of the ribitol (along the C3/C4 to PO4
backbone).
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Figure 5.14: Examples of conformations of αdGlcp(1→3)αlRhap(1→3)dRibol5P and
αdGlcp(1→3)αlRhap(1→4)dRibol5P corresponding to the labeled wells of the PMFs (Fig 5.12 (b and
c))
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5.3 Discussion
Serogroup 6 oligosaccharides were divided into disaccharide components in two
ways: firstly treating ribitol-phosphate as a standard residue and secondly treat-
ing it as a substituent onto another residue (Figure 5.1):
1: dRibol5P(O→2)αdGalp (6A and 6B)
1′: dRibol5P(O→2)αdGlcp (6C and 6D)
2: αLRhap(1→3)dRibol5P (6A and 6C)
2′: αLRhap(1→4)dRibol5P (6B and 6D)
3: αdGalp(1→3)αdGlcp (6A and 6B)
3′: αdGlcp(1→3)αdGlcp (6C and 6D)
4: αdGlcp(1→3)αlRhap (6A, 6B, 6C and 6D)
and
r3: dRibol5P(O→2)αdGalp(1→3)αdGlcp (6A and 6B)
r3′: dRibol5P(O→2)αdGlcp(1→3)αdGlcp (6C and 6D)
4r: αdGlcp(1→3)αlRhap(1→3)dRibol5P (6A and 6C)
4r′: αdGlcp(1→3)αlRhap(1→4)dRibol5P (6B and 6D)
The PMF plots of the disaccharides are in agreement with the exo-anomeric
effect which states that the φ angle for the non-reducing sugar α-linked disaccha-
rides (2, 2′, 3, 3′ and 4) is approximately -60◦ or 180◦.47,94 The serotype points of
difference 1 and 1′, 3 and 3′ as well as r3 and r3′ produce nearly identical PMF
plots. This is to be expected with disaccarides 3 and 3′ as these disaccharides
differ in the hydroxyl orientation at C4 of their glucose and galactose residues, a
difference which is far removed from their glycosidic linkage and as a result has
minimal effects. Even when the C4 hydroxyl is closer to the linkage (in disaccha-
rides 1 and 1′ and r3 and r3′) a minimal difference is seen in the PMFs. This
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would suggest that the change between a glucose and a galactose residue would
minimally alter the structure of the higher order oligosaccharides.
The results of disaccharide pairs 2 and 2′ and 4r and 4r′ exhibit the greatest
point of difference in these serotypes. Comparing disaccharides 2 and 2′, the
αlRhap(1→3)dRibol5P linkage has more conformational options, with a low en-
ergy anti/syn region, than its (1→4) counterpart. When ribitol-phosphate was
added as a substituent to the αdGlcp(1→3)αlRhap disaccharide (4r and 4r′),
the disaccharide with the (1→3) linked substituent exhibited greater conforma-
tional freedom with an extra syn/syn well than the molecule with the (1→4)
linked substituent. The greater conformational freedom observed for the (1→3)
ribitol substituted disaccharide, can be explained by the longer ribitol backbone
(C3 to PO4 as opposed to C4 to PO4 in a (1→4) linkage). The longer (1→3)
linked ribitol backbone in rhamnose-ribitol, affords more rotational freedom to
position the phosphate motif to form stabilizing hydrogen bonds with hydroxyls
adjacent to the glucose-rhamnose glycosidic linkage than the (1→4) substituent
linkage would.
The results show that the biggest point of difference between the serotypes
is between: αlRhap(1→3)dRibol5P (6A and 6C) and αlRhap(1→4)dRibol5P
(6B and 6D). There is minimal difference seen between the αdGalp (6A and 6B)
and αdGlcp (6C and 6D) residues. Ribitol-phosphate is a flexible residue which
has the ability to form a variety of stabilizing interresidue hydrogen bonds which
change the energy landscapes of the disaccharides. However in an oligosaccharide,
with ribitol bonded to both a rhamnose and a glucose/galactose residue, it is
expected that this flexibility will be greatly reduced. From this study of the
glycosidic linkages, it is expected that the greatest structural differences within
the serogroup will be observed between serotype pairs: 6A and 6D, and 6B and
6C.
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Chapter 6
Oligosaccharide Structures of
Serogroup 6
The previous chapter gave insight into the conformation of the component dis-
accharides of S.pneumoniae serogroup 6. This chapter extends these results to
oligosaccharides, looking at the effect of interresidue interaction on the preferred
conformation of the serogroup 6 oligosaccharides. The differences between the
four serotypes are highlighted in the schematic in Figure 6.1: a galactose/glucose
residue and a (1→3)/(1→4) linkage. The PMFs of all the linkage constituents
of serogroup 6 allowed identification of the global minimum conformations which
were used to build likely starting structures for the 6A-D oligosaccharides.
6.1 Building of the Oligosaccharides
Two oligosaccharide structures were built for each serotype: the first using di-
hedral values from the calculations for unsubstituted disaccharides for all the
glycosidic linkages and the second using values for the dRibol5P substituted dis-
accharides (Figures 6.2 - 6.5). Each of the oligosaccharides structures consisted of
three repeating units (12 residues). Oligosaccharides built with the unsubstituted
dihedral values are henceforth labeled 6A - 6D, while those built with dRibol5P
substituted dihedral values are primed (6A′ - 6D′).
In most cases, the disaccharides were set to their global minimum φ/ψ values,
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Figure 6.1: Schematic of serogroup 6, highlighting the differences between the four serotypes. The red boxes
indicate a galactose residue, blue indicates a glucose residue, purple indicate a (1→3) linkage and green indicate
a (1→4) linkage
as calculated from the PMFs in Chapter 5. However, for 6A′ and 6C′ this choice of
dihedrals leads to self-intersecting molecular structures. Therefore, in these cases,
the flexible ribitol-phosphate-galactose (6A′) or ribitol-phosphate-glucose (6C′)
dihedral angles were rotated to the secondary low energy well in the linkage, as
shown in Figures 6.2 and 6.4. This ribitol-phosphate-galactose/glucose dihedral
shows the greatest distribution of equivalent low energy wells across the φ/ψ
conformational space. The dRibol5P(O→2)αdGalp/αdGlcp dihedrals in 6A′
and 6C′ were set to the lowest energy well that resolved the self-intersection: well
D for 6A′ and well C for 6C′.
67
Figure 6.2: Three repeating unit 6A ([→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]) oligosac-
charides built from disaccharide conformations. The global minimum is indicated by the black diamonds. Note
that for 6A′, the dRibol5P(O→2)αdGalp linkage was set to the secondary minimum D.
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Figure 6.3: Three repeating unit 6B ([→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]) oligosac-
charides built from disaccharide conformations. The global minimum is indicated by the black diamonds.
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Figure 6.4: Three repeating unit 6C ([→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]) oligosac-
charides built from disaccharide conformations. The global minimum is indicated by the black diamonds. Note
that for 6C′, the dRibol5P(O→2)αdGlcp linkage was set to the secondary minimum C.
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Figure 6.5: 3 repeating unit 6D ([→2)αdGlcp(1→3)αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]) oligosaccha-
rides built from disaccharide conformations. The global minimum is indicated by the black diamonds.
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6.2 Serotype 6A
Figure 6.6 details the glycosidic linkage conformations for residues in the middle
repeating unit of serotype 6A ([→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→3)
dRibol5P(O→]) throughout the course of the 500 ns simulations. The two sim-
ulations started from 6A and 6A′ conformations, produced similar equilibrium
distributions, indicating that the simulations have reached convergence.
6A′ populated the same conformational regions as 6A (Figure 6.6). The gly-
cosidic linkages exclusively occupy the low energy regions of the PMF, with the
flexible ribitol-phosphate linkages showing the greatest distribution (but remain-
ing within the low energy wells calculated on the PMFs). This indicates that
the PMF for the glycosidic linkages is a fairly reliable measure of the possi-
ble conformations of an oligosaccharide; the intermolecular interactions in the
oligosaccharides do not make dramatic alterations. It is interesting to note that
the A,B,C wells in linkage 1 (Figure 6.6) are not occupied in either simulation
despite 6A starting from the A conformation. Rather, this linkage populates the
D well (the conformation to which the linkage in 6A′ was set to avoid self in-
tersection) and is distributed along φ from well D. Just as with the 3 linkage in
6A, the r3 linkage of 6A′ also occupies the low energy regions of the calculated
PMF. The low energy regions of the PMFs of 3 and r3 are similar and as such
the results are as expected. Likewise, the 4r linkage in 6A′ occupies the similar
region as 4 in 6A, that is the low energy regions of the unsubstituted linkage is
occupied.
Conformational set: 1 (•) 2 ()
φ, ψ (◦) φ, ψ (◦)
αdGalp(1→3)αdGlcp -27, -169 -29, 43
αdGlcp(1→3)αlRhap -37, -27 -35, -21
αlRhap(1→3)dRibol5P 35, 1 33, 33
dRibol5P(O→2)αdGalp -157, -35 27, -31
Table 6.1: Dihedral values used to build 20mers in Figure 6.7; values of the glycosidic linkages between the
two structures are coloured in blue when they are located in different regions.
It is clear from the trajectories in Figure 6.6, that galactose linkages 1 and
3 have two different conformational preferences. Investigation of the trajectories
revealed that these disaccharide conformations are paired, resulting in two distinct
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Figure 6.6: Progression of glycosidic linkages of the middle repeating unit of serotype 6A and 6A′. • and 
indicate the dihedrals of the two prevalent conformations of 6A.
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Figure 6.7: Snapshots of the two most prevalent conformations of the last 100 ns of the MD simulations of
6A (the • and  regions on Figure 6.6), and the two possible 20mer structures of serotype 6A, built from the
conformations. The darker segments indicate layers which are in the “front” plane while the lighter structures
lie in the “back” plane.
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prevalent structures for the 6A oligosaccharide: the  conformation with linkage
3 in a syn/syn conformation is paired with linkage 1 in a syn/syn position, and the
• conformation with linkage 3 in a syn/anti conformation is paired with linkage
1 in an anti/syn position. The dihedral values of the two resulting conformations
are labeled on the PMF plots with •s and s (Figure 6.6 and Table 6.1). From
these most prevalent conformations from the last 100 ns two 20mer (5 repeating
units) of serotype 6A were built and minimized and are shown in Figure 6.7 along
with the corresponding • and  6A 20mers.
Conformations • and  both represent stacked structures with the pyran
residues of each repeating unit layered upon each other and with the ribitol-
phosphate acting as a flexible joint between each of the layers. In the • confor-
mation, the resulting structure is more cramped, as the layers are not co-planar,
but alternate between a front and back layer. The layers of the  structure are
co-planar, with every other phosphate aligned on either side of the stack. Con-
formation  adopts a ladder like structure with each pyran layer as a rung. With
both structures, the direction (non-reducing end to reducing end) of the pyran
residues of each repeating unit switches every layer. This is indicated with the ar-
rows on the schematic in Figure 6.7. For both conformations, the phosphates are
on the outer edges of the structure making these charged motifs highly exposed.
6.3 Serotype 6B
Figure 6.8 shows plots for 6B ([→2)αdGalp(1→3)αdGlcp(1→3)αlRhap(1→4)
dRibol5P(O→]) detailing the glycosidic linkages of the middle repeating unit
of 6B serotypes through out the 500ns MD simulation. The two trajectories
show that both structures converge, with their linkages occupying similar dihedral
regions at the end of the simulation.
The linkages 3 and r3 settle in similar conformational regions which sit in the
primary energy well of both the PMFs. While the 4r′ linkage (6B′) converged
away from the minimum on the PMF, the region of convergence is similar to
that of linkage 4 which falls within the primary energy well. The ribitol linkages
1 and 2′ both converge to similar regions in both 6B and 6B′ starting confor-
mations, however they have shifted away from their primary low energy well.
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The higher concentration of the red points on the PMF plots of 6B′ shows that
the oligosaccharides converged faster than the 6B oligosaccharide. While both
oligosaccharides eventually converge to same regions (with linkage 1 and 3 in
syn/syn conformations- labeled  in Figure 6.8) , it is clear from the trajectories,
that an alternate configuration exists with linkage 1 in the anti/syn conformation
and linkage 3 in a syn/anti conformation (labeled • in Figure 6.8).
Two 20mer (5 repeating units) of serotype 6B were built and minimized with
these two prevalent conformations (Table 6.2) and the structures are shown in
Figure 6.9.
Conformational set: 1 (•) 2 ()
φ, ψ (◦) φ, ψ (◦)
αdGalp(1→3)αdGlcp -21, 31 -33,-19
αdGlcp(1→3)αlRhap -45,-39 -71,-65
αlRhap(1→4)dRibol5P 1,-41 25,-47
dRibol5P(O→2)αdGalp 41,1 41,1
Table 6.2: Dihedral values used to build 20mers shown in Figure 6.9; values of the glycosidic linkages between
the two structures are coloured in blue when they are located in different regions.
The 6B• conformation shows a ladder like structure, however with the ribitol-
phosphates acting as rungs. However, the  conformation shows a somewhat he-
lical structure interrupted by the linear ribitol-phosphates where the phosphates
are almost aligned vertically and the repeating units projecting in opposite di-
rections. The direction (non-reducing to reducing end) of the pyran residues of
the repeating units for both conformations is maintained along a plane. Unlike
6A, the charged phosphates in 6B are in the centre of the structure making them
more sheltered than the phosphates in 6A.
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Figure 6.8: Progression of glycosidic linkages of the middle repeating unit of serotype 6B and 6B′. • and 
indicate the dihedrals of the two prevalent conformations of 6B.
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Figure 6.9: Two possible 20mer structures of serotype 6B, built from the most prevalent conformations of the
last 100 ns of the MD simulations of 6B and 6B′ (the • and  regions on Figure 6.8). The darker segments
indicate layers which are in the “front” plane while the lighter structures lie in the “back” plane.
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6.4 Serotype 6C
The glycosidic linkages of the middle repeating unit of 6C ([→2)αdGlcp(1→3)
αdGlcp(1→3)αlRhap(1→3)dRibol5P(O→]) from both starting conformations
6C and 6C′ explore the same regions during the course of the simulation. However,
not all of the corresponding linkages converge to the same regions (Figure 6.10).
Linkages 3′ (in 6C) and r3′ (in 6C′) both explored the same φ/ψ regions,
however they converged to different areas of the map. In the oligosaccharide
built from the unsubstituted disaccharide values (6C), linkage 3′ converged to
the primary syn/syn low energy well on the PMF, the corresponding linkage in
the 6C′ oligosaccharide converged to the syn/anti region on the PMF. Linkages
4 and 4r explored the same region and converged to similar regions by the end
of the simulation. The ribitol linkages (linkage 1′ and 2) explored regions away
from the low energy regions calculated in Chapter 5, similar to what is seen with
serotype 6A and 6B. In both 6C and 6C′, linkage 2 converged to similar regions.
Linkage 1′ in 6C converges to a syn/syn region, while the corresponding linkage
in 6C′ converges to an anti/syn region.
Conformational set: 1 (•) 2 ()
φ, ψ (◦) φ, ψ (◦)
αdGlcp(1→3)αdGlcp -27,-167 -51,-25
αdGlcp(1→3)αlRhap -43,-39 -29,-13
αlRhap(1→3)dRibol5P 33,23 27,31
dRibol5P(O→2)αdGlcp -157,1 1,-45
Table 6.3: Dihedral values of the two most prevalent conformations which were used to build 20mers in Figure
6.11; values of the glycosidic linkages between the two structures are coloured in blue when they are located in
different regions.
Like 6A, the trajectories of 6C in Figure 6.10 show that glucose linkages 1
and 3 have two separate conformational pair preferences: linkage 3 in a syn/syn
conformation is paired with linkage 1 in a syn/syn position (the  conformation),
while linkage 3 in a syn/anti conformation is paired with linkage 1 in a anti/syn
position (the • conformation). The dihedral values of the the two resulting
conformations are labeled on the PMF plots with •s and s (Figure 6.10 and
Table 6.3).
The 20mer oligosaccharides were built and minimized using the most preva-
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Figure 6.10: Progression of glycosidic linkages of the middle repeating unit of serotype 6C and 6C′. • and 
indicate the dihedrals of the two prevalent conformations of 6C.
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Figure 6.11: Snapshots of the two most prevalent conformations of the last 100 ns of the MD simulations of
6C (the • and  regions on Figure 6.10), and the two possible 20mer structures of serotype 6A, built from the
conformations. The darker segments indicate layers which are in the “front” plane while the lighter structures
lie in the “back” plane.
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lent conformations from the last 100 ns, the values of which are shown in Table
6.3. Figure 6.11 shows these structures; conformation  adopts a ladder stacked
structure similar to a 6A structure, while the • is slightly helical. Just as with
the 6A structures, the 6C  structure has phosphates on the outside of the struc-
ture making the phosphates easily accessible. The 6C • conformation has nearly
helical structure with the phosphates in the middle of the helix. This is unusual
for the (1→3) linked serotypes (6A and 6C) as the phosphates in this structure
have now been sheltered.
6.5 Serotype 6D
Molecular dynamics was conducted on the final serotype 6D ([→2)αdGlcp(1→3)
αdGlcp(1→3)αlRhap(1→4)dRibol5P(O→]) and the glycosidic linkages of the
middle residue were plotted on the PMFs calculated in Chapter 5. Just as for
the other three serotypes, both 6D and 6D′ starting conformations explored the
same regions during the course of the simulation (Figure 6.12).
In 6D and 6D′, linkages 3′ and r3′ both explored the same regions, however
they converged to different areas of the map. For 6D, linkage 3′ converged to the
primary syn/syn low energy well on the PMF, while the corresponding linkage
in the 6D′ oligosaccharide converged to the syn/anti region on the PMF. On the
other hand linkages 4 and 4r′ explored and converged to the same region by the
end of the simulation. This region of convergence is removed from the low energy
well in 4r′, but they both lie in the syn/syn primary low energy well for the
4 glycosidic linkage. As usual, the ribitol linkages (linkage 1′ and 2′) explored
regions away from the low energy regions calculated in Chapter 5. In both 6D
and 6D′, linkage 2′ converged to similar regions, which for the first time is the
low energy well calculated in Chapter 5. Linkage 1′ in 6D converged to a syn/syn
region, while the corresponding linkage in 6D′ converged to an anti/syn region.
Just as for the other serotypes the oligosaccharides have two prevalent con-
formations with linkage 1 and 3 adopting conformational pairs (Figure 6.12):
syn/syn for linkage 1 with syn/syn for linkage 2 ( conformation) and syn/anti
for linkage 1 with anti/syn for linkage 2 (• conformation). The 20mer oligosac-
charides were built using the most prevalent dihedral definitions from the middle
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Figure 6.12: Progression of glycosidic linkages of the middle repeating unit of serotype 6C and 6C′. • and 
indicate the dihedrals of the two prevalent conformations of 6D.
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Figure 6.13: Snapshots of the two most prevalent conformations of the last 100 ns of the MD simulations of
6D (the • and  regions on Figure 6.12), and the two possible 20mer structures of serotype 6A, built from the
conformations. The darker segments indicate layers which are in the “front” plane while the lighter structures
lie in the “back” plane.
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Conformational set: 1 (•) 2 ()
φ, ψ (◦) φ, ψ (◦)
αdGlcp(1→3)αdGlcp -31,-159 -37,1
αdGlcp(1→3)αlRhap -51,-39 -39,-33
αlRhap(1→4)dRibol5P 33,29 35,33
dRibol5P(O→2)αdGlcp -173,-27 43,1
Table 6.4: Dihedral values used to build 20mers in Figure 6.13; values of the glycosidic linkages between the
two structures are coloured in blue when they are located in different regions.
repeating unit of the last 100 ns of the simulations (Table 6.4).
Figure 6.13 shows these molecules, which exhibit two possible co-planar struc-
tures for the 6D oligosaccharide. Conformation • adopts a ladder-like layered
structure similar to 6B, where the pyran residues of each repeating do not stack
upon each other, but rather the ribitol-phosphate residues stack forming the
“rungs” of the ladder. The  conformation is similar to •, however the pyran
residues are more skewed. Also like 6B, the direction (the non-reducing to re-
ducing end) of the pyran residues do not change with each repeating unit (as
indicated by the arrows on Figure 6.13).
6.6 Discussion
In serotypes 6A and 6B a galactose residue is linked to two residues: αdGalp
(1→3)αdGlcp and dRibol5P(O→2)αdGalp, which is replaced by a glucose residue
in 6C and 6D. Nearly identical PMFs were calculated for the galactose and corre-
sponding glucose counterpart disaccharides, and as such it was expected that the
galactose/glucose substitution would have a minimal effect on the overall serotype
structure.
In order to observe the structural difference caused by a galactose/glucose
difference, serotype pairs 6A/6C and 6B/6D were compared as the only point of
difference within the pair is the galactose or glucose residue. From the results
of the most populated conformations of the glycosidic linkages from the last 100
ns of the MD simulations, it would appear that the two galactose and glucose
residues are likely to exist in two combinations:
The serotype pairs 6A/6C and 6B/6D show similar stacked structures. The
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the  conformation:
αdGalp/αdGlcp(1→3)αdGlcp (syn,anti) and
dRibol5P(O→2)αdGalp/αdGlcp (anti,syn)
or the • conformation:
αdGalp/αdGlcp(1→3)αdGlcp (syn,syn) and
dRibol5P(O→2)αdGalp/αdGlcp (syn,syn)
6A/6C pairs have pyran residues of each repeating unit layered upon each other.
6C shows an interesting alternate structure in the 6C-• conformation (not seen
in 6A) with the helical structure and phosphates in the centre. The 6C/6D pair
are the most similar of the serogroup: a ladder like stacked structure and an
alternate helical-type structure.
The structural similarity of serotype pairs 6A/6C and 6B/6D shows that
the biggest difference within the serogroup is the linkage between rhamnose and
ribitol-phosphate. A rhamnose residue is linked to the ribitol-phosphate via an
α(1→3) linkage in 6A and 6C and with an α(1→4) linkage in 6B and 6D. This
difference can be seen in the stacking of the ladder like structures: pyran layers
for the α(1→3) and ribitol-phosphate layers for the α(1→4) linkages. Serotypes
6B and 6D are also more extended structures (both stacked and helical struc-
tures) than 6A and 6C structures. The difference in saccharide extension can be
explained by the extra length of the α(1→3) linkage backbone (from C3 to the P)
which has greater conformational freedom to bend and thus forms a compressed
structure when compared to the shorter backbone (C4 to P) of the α(1→4) link-
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ages.
Ribitol-phosphate, also known as teichoic acid, is an important and com-
mon motif in bacterial polysaccharides. While the role of teichoic acids is not
fully understood, it is clear that these anionic moieties play an important role
in bacterial virulence, membrane integrity, and cell scaffolding and thus vaccine
efficacy.95–98 Therefore, the position of the phosphates in these serotypes is im-
portant in studying their structure. Serotypes 6A and 6C have the phosphates
placed on the exterior of the structures making the anionic motif easily accessible,
while in the 6B and 6D structures have less accessible phosphates in the interior
of the structures. The anomaly is the alternate helical 6C structure which has
sheltered phosphates. The limited number of conformational studies conducted
on sugar phosphates show that the phosphate-sugar linkage is highly flexible.99
The distributions in conformation of the dRibol5P(O→2)αdGalp/αdGlcp
linkages during the course of these simulations shifted away from the global min-
ima calculated in Chapter 4, but similar to that observed by Ho¨o¨g et al. with
α and ψ (in Ho¨o¨g) corresponding to φ and ψ in the glycosidic linkage.100 This
difference can be explained by the fact that the phosphodiester linkages inves-
tigated by Ho¨o¨g et al. involved two pyranosyl residues which are more rigid as
opposed to one pyranose residue and one linear alditol residue (the disaccharides
investigated in Chapter 5) as in the serogroup 6 saccharides. In the serotypes the
interresidue effects reduce the flexibility of the ribitol therefore accounting for the
distribution of the linkage conformation in the oligosaccharides.
What is clear from these results is that pairs 6A/6C and 6B/6D have simi-
lar structures and as such it is expected that serotypes 6A and 6B would cross
protect against non-vaccine types 6C and 6D. This is consistent with current lit-
erature, however as PCV-13 is newly licensed (2010) and serotypes 6C and 6D
are newly discovered, the clinical efficacy of this cross-protection has yet to be
measured.13,29,41,42,101 Serotype 6B does offer some cross-protection against 6A,
however these results offer no obvious structural basis to explain this. Further
simulations with explicit water and counter ions may shed light on this cross-
protection.
These results are limited, as time constrains did not permit for the serotypes
to be simulated in a water box with counter ions. The addition of counter ions
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to the simulation would have been especially useful as the phosphate negative
charges on these oligosaccharides are key to their behaviour in somatic environ-
ments. However the fact that both simulations (non-primed and primed for each
serotype) explored similar regions regardless of the starting structure is encourag-
ing. These simulations also give insight into ribitol-phosphate and phosphodiester
modelling, on which limited previous work has been conducted.
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Chapter 7
Conclusions and Future Work
The aim of this project was to structurally characterize the four serotypes of
Streptococcus pneumoniae serogroup 6 and to identify the tertiary structural dif-
ferences brought on by the slight differences in primary structure within the
serogroup: a αdGalp/αdGlcp residue difference and a αlRhap-dRibol5P (1→3)/
(1→4) linkage difference. The following questions were asked:
1. What effect does the αlRhap-dRibol5P (1→3)/(1→4) linkage change have
on the structure of the serotypes?
2. What effect does a galactose/glucose residue change have on the structure
of the serotypes?
3. Can a systematic approach to computational modelling of serogroup 6 pro-
vide insight into cross-protection observed between serotypes 6A-D?
The first step was to establish the low energy conformations of the disaccharide
subunits of the serogroup. A metadynamics routine, using φ and ψ dihedral angles
as collective variables, was used to produce potential of mean force landscapes
that give insight into the low energy conformations of the disaccharides. Two
classes of PMF landscapes were calculated: the first for disaccharides resulting
from a na¨ıve division of the serogroup, and the second, resulting from treating
ribitol-phosphate as a substituent to adjacent residues rather than a residue itself.
These calculations showed that, within both disaccharide classes, the disac-
charides with a αdGalp/αdGlcp residue difference showed nearly identical PMF
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plots, indicating that this residue difference would have little effect on the over-
all structure of the oligosaccharides. The biggest change in energy landscapes
was between residues with a differing αlRhap-dRibol5P (1→3)/(1→4) linkage,
suggesting that this is the biggest point of difference within the serogroup.
Three repeating unit (12 residues) long oligosaccharides of serogroup 6 were
built with torsion angles set to the conformations found for the global minima
calculated from the disaccharide free energy calculations. Molecular Dynamics
simulations with implicit solvation were conducted on these oligosaccharides and
the dihedral angles of the glycosidic linkages from the middle repeating unit were
plotted on their respective energy landscape. The conformations of the glycosidic
linkages throughout the course of the MD simulations occupied the low energy
regions on the energy landscapes, showing that the disaccharide plots are a good
indicator of allowed conformations for dihedral linkages in an oligosaccharide. The
dRibol5P(O→2)αdGalp/αdGlcp linkages occupied conformations away from the
calculated global minima, however they did occupy low energy regions that agreed
with other studies of similar linkages.
MD simulations on all four serotypes showed that the oligosaccharides had two
conformational preferences. Five repeating-unit long oligosaccharides were built
using these two conformational preferences and were subsequently minimized.
These 20mers showed structural similarities between serotypes 6A and 6C and
between 6B and 6D. Serotypes 6A and 6C have a αdGalp/αdGlcp difference but
they both have a αlRhap(1→3)dRibol5P linkage. Both serotypes have a stacked
ladder-like structure, with the phosphate motifs exposed on the outside of the
structure. 6C also adopts an alternate helical structure not seen in 6A. Serotypes
6B and 6D have very similar structures and adopt either a regular ladder-like
structure or an extended helical structure. In both cases the phosphates are more
hidden than in the 6A/6C pair, being located in the middle of the “rungs” in the
center of the structures. The results of the 20mer are in agreement with prediction
from the disaccharide energy landscapes: the biggest points of difference within
the serogroup is the αlRhap-dRibol5P (1→3)/(1→4) linkage. The structural
information from this study suggests that serotype 6A will offer cross-protection
against 6C and serotype 6B against 6D, as suggested by McEllistrem et. al.29
However no structural relationships were seen between 6A and 6B to explain the
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cross protection serotype 6B offers 6A.
However, this study has not considered the possible effects of solution and
counter-ions on the conformations of serogroup 6. Now that low energy con-
formations have been identified for the four serotypes, the next step will be to
undertake time consuming simulations of these molecules in solution.
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